solifenacin succinate profile

Solifenacin Succinate: A quinuclidine and tetrahydroisoquinoline derivative and selective M3 MUSCARINIC ANTAGONIST. It is used as a UROLOGIC AGENT in the treatment of URINARY INCONTINENCE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	216457
CHEBI ID	32151
SCHEMBL ID	109333
MeSH ID	M0554458

Synonym
HY-A0002
solifenacin (succinate)
ym-53705
vesicare od
solifenacin succinate
vesikur
vesicare
solifenacin succinate (jan/usan/inn)
D01269
242478-38-2
vesicare (tn)
2(1h)-isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3r)-1-azabicyclo(2.2.2)oct-3-yl ester, (1s)-, butanedioate (1:1)
butanedioic acid, cmpd. with (1s)-(3r)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1h)-isoquinolinecarboxylate (1:1)
solifenacin succinate [usan]
butanedioic acid, compd with (1s)-(3r)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1h)-isoquinolinecarboxylate (1:1)
quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate
ym-67905
ym67905
[(3r)-1-azabicyclo[2.2.2]octan-3-yl] (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate; butanedioic acid
A819262
butanedioic acid; (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylic acid [(3r)-1-azabicyclo[2.2.2]octan-3-yl] ester
AKOS015994745
unii-kka5dld701
quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylatemonosuccinate
kka5dld701 ,
solifenacin succinate salt
solifenacin succinate [ep monograph]
solifenacin succinate [mart.]
solifenacin succinate [vandf]
solifenacin succinate [who-dd]
solifenacin succinate [mi]
vesicare ls
solifenacin succinate [jan]
solifenacin succinate [orange book]
solifenacin succinate [usp-rs]
AM84825
CS-0371
S3048
MLS006010416
smr004701445
SCHEMBL109333
KS-1286
(1s)-(3r)-1-azabicyclo[2.2.2]oct-3-yl-3,4-dihydro-1-phenyl-2(1h)-isoquinolinecarboxylate succinate
RXZMMZZRUPYENV-VROPFNGYSA-N
S0944
[(3r)-1-azabicyclo[2.2.2]octan-3-yl] (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate;butanedioic acid
mfcd00954234
succinate, solifenacin
solifenacin succinate; (3r)-1-azabicyclo[2.2.2]octan-3-yl (1s)-1-phenyl-3,4-dihydroisoquinoline-2(1h)-carboxylate hydrogen butanedioate
CHEBI:32151
1-azabicyclo[2.2.2]octan-8-yl (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate butanedioic acid
solifenacin for system suitability, europepharmacopoeia (ep) reference standard
solifenacin succinate, >=98% (hplc)
solifenacin succinate, united states pharmacopeia (usp) reference standard
solifenacin succinate, europepharmacopoeia (ep) reference standard
SW219141-1
AS-35288
(3r)-quinuclidin-3-yl (1s)-1-phenyl-3,4-dihydroisoquinoline-2(1h)-carboxylate succinate
Q374826
(s)-(r)-quinuclidin-3-yl 1-phenyl-3,4-dihydroisoquinoline-2(1h)-carboxylate succinate
HMS3887A13
CCG-269551
EX-A4170
butanedioic acid--1-azabicyclo[2.2.2]octan-3-yl 1-phenyl-3,4-dihydroisoquinoline-2(1h)-carboxylate (1/1)
DTXSID30947075
isoprenalinoe sulfate
(r)-quinuclidin-3-yl (s)-1-phenyl-3,4-dihydroisoquinoline-2(1h)-carboxylate
A881133
BS164410
solifenacin succinate- bio-x
(s)-(r)-quinuclidin-3-yl1-phenyl-3,4-dihydroisoquinoline-2(1h)-carboxylatesuccinate
solifenacin succinate5 mg
solifenacine succinate
solifenacin succinate (ep monograph)
solifenacin succinate (mart.)
solifenacin succinate10 mg
solifenacin succinate tablets
solifenacin succiate
solifenacin succinate (usp-rs)
vesicarels

Excerpt	Reference	Relevance
"Solifenacin succinate is a once-daily oral antimuscarinic for the treatment of OAB."	( Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Brunton, S; Kuritzky, L, 2005)	1.26
"Solifenacin succinate is a novel antimuscarinic agent approved in Europe and the US for the treatment of men and women with OAB."	( Solifenacin in overactive bladder syndrome. Payne, CK, 2006)	1.06
"Solifenacin succinate (YM905) is a new, once-daily, orally administered muscarinic receptor antagonist designed to treat overactive bladder. "	( Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers. Krauwinkel, WJ; Smith, NN; Smulders, RA; Swart, PJ, 2006)	1.78
"Solifenacin succinate is a once daily, bladder selective antimuscarinic available in two doses (5 and 10 mg)."	( Solifenacin significantly improves all symptoms of overactive bladder syndrome. Cardozo, L; Chapple, CR; Govier, FE; Steers, WD, 2006)	1.06
"Solifenacin succinate is a new once-daily antimuscarinic agent that is an effective and well-tolerated treatment option for patients who have overactive bladder."	( Solifenacin. Kreder, KJ, 2006)	1.06
"Solifenacin succinate (SOL) is a competitive muscarinic-receptor antagonist approved by the US Food and Drug Administration in late 2004 for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency."	( Solifenacin succinate for the treatment of symptoms of overactive bladder. Maniscalco, M; Singh-Franco, D; Torres-Colón, R; Wolowich, WR, 2006)	2.5
"Solifenacin succinate is a novel muscarinic receptor antagonist used for the treatment of overactive bladder (OAB). "	( Effects of intravenously and orally administered solifenacin succinate (YM905) on carbachol-induced intravesical pressure elevation and salivary secretion in mice. Noguchi, Y; Ohtake, A; Okutsu, H; Sasamata, M; Sato, S; Suzuki, M, 2007)	2.04

Excerpt	Reference	Relevance
"Solifenacin succinate treatment was terminated in 3 patients owing to dry eye in 1 patient, increased IOP in 1 patient, and systemic side effects in 1 patient."	( Changes in intraocular pressure and tear secretion in patients given 5 mg solifenacin for the treatment of overactive bladder. Coban, S; Demirbas, M; Demirci, H; Guzelsoy, M; Turkoglu, AR; Yener, NP, 2017)	1.18

Excerpt	Reference	Relevance
" The most commonly reported adverse events were dry mouth, blurred vision, and headache."	( Pharmacokinetics and safety of solifenacin succinate in healthy young men. Huang, M; Krauwinkel, WJ; Smulders, RA; Swart, PJ, 2004)	0.61
" No deaths or serious adverse events occurred during the study."	( Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency. Hoon, TJ; Krauwinkel, WJ; Smith, NN; Smulders, RA, 2007)	0.34
"As such high-risk patients have not been well represented in most randomized trials of muscarinic receptor antagonists, we investigated whether the muscarinic receptor antagonist solifenacin alters heart rate or has other cardiovascular adverse effects during routine use in OAB patients."	( Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study. de la Rosette, JJ; Michel, MC; Vogel, M; Wetterauer, U, 2008)	0.35
" Secondary outcome measures were blood pressure and overall adverse events, which were systematically recorded before, during (after 1 week) and at study end; in many cases, an ECG was also conducted."	( Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study. de la Rosette, JJ; Michel, MC; Vogel, M; Wetterauer, U, 2008)	0.35
" Dry mouth was the most common adverse event; its incidence was the lowest in SOL5 group (7."	( Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study. Choo, MS; Jung, HC; Kim, HJ; Kim, JC; Kim, YH; Lee, JB; Lee, JG; Lee, JZ; Lee, KS; Na, YG; Paick, JS; Seo, JT, 2008)	0.66
" Safety assessment was based on adverse event reporting."	( [Efficacy and safety of solifenacin in daily clinical practice--clinical study phase IV]. Fabisovský, M; Havránek, O; Krhut, J; Míka, D; Valis, P, 2008)	0.35
" Adverse events were reported in 19 patients (5."	( [Efficacy and safety of solifenacin in daily clinical practice--clinical study phase IV]. Fabisovský, M; Havránek, O; Krhut, J; Míka, D; Valis, P, 2008)	0.35
" Adverse events were monitored throughout the study."	( Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Fakhoury, A; Fincher, R; He, W; Kaplan, SA; McCammon, K, 2009)	0.35
"The most frequent adverse events in the solifenacin plus tamsulosin and placebo plus tamsulosin groups were dry mouth (7% and 3%, respectively) and dizziness (3% and 2%, respectively)."	( Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. Fakhoury, A; Fincher, R; He, W; Kaplan, SA; McCammon, K, 2009)	0.35
" Adverse events and changes of urodynamic values and clinical data were compared between the solifenacin and tolterodine groups."	( Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. Chang, TC; Chen, CH; Hsiao, SM; Lin, HH; Wu, WY; Yu, HJ, 2011)	0.37
"Both solifenacin and tolterodine had similar urodynamic effects, therapeutic efficacy and adverse events in treating women with overactive bladder syndrome; however, tolterodine had a greater effect in increasing heart rate than solifenacin."	( Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. Chang, TC; Chen, CH; Hsiao, SM; Lin, HH; Wu, WY; Yu, HJ, 2011)	0.37
" The most common adverse effects was dry mouths."	( Efficacy and safety of solifenacin to treat overactive bladder symptoms in patients with idiopathic normal pressure hydrocephalus: an open-label, multicenter, prospective study. Cho, KS; Chung, JH; Ha, US; Ham, WS; Han, JH; Kang, DH; Lee, JY; Lee, SH; Lee, SW; Park, J; Yoo, TK, 2012)	0.38
" The most common adverse effects with solifenacin were dry mouth and constipation."	( The efficacy and safety of solifenacin in patients with overactive bladder syndrome. Banović, M; But, I; Goldstajn, MS; Oresković, S, 2012)	0.38
" The AMs used to treat OAB differ in their pharmacological profiles, which may affect their potential for causing adverse effects (AEs)."	( Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. Alessandri, F; Candiani, M; Ferrero, S; Leone Roberti Maggiore, U; Origoni, M; Remorgida, V; Salvatore, S; Venturini, PL, 2012)	0.38
"5%) patients discontinued treatment due to adverse events in group I and group S, respectively."	( Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study. Fukumoto, K; Hara, R; Koide, T; Miyaji, Y; Nagai, A; Yokoyama, T, 2013)	0.39
" Adverse events were monitored throughout the study."	( Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency. Fakhoury, A; Fincher, R; He, W; Kaplan, SA; McCammon, K, 2013)	0.39
"The most frequent adverse events in the solifenacin plus tamsulosin and placebo plus tamsulosin groups were dry mouth (7% and 3%, respectively) and dizziness (3% and 2%, respectively)."	( Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency. Fakhoury, A; Fincher, R; He, W; Kaplan, SA; McCammon, K, 2013)	0.39
"The incidence rates of overall adverse event, dry mouth, constipation and blurred vision of the experimental group (solifenacin 5 mg once per day) was 26."	( [Safety of solifenacin and tolterodine in the treatment of overactive bladder: a meta-analysis]. Jiang, XZ; Xu, C; Xu, ZS; Zhang, NZ; Zhao, HF, 2012)	0.38
"Dry mouth is the most common adverse event of solifenacin (5 mg once per day) and tolterodine (2 mg twice per day)."	( [Safety of solifenacin and tolterodine in the treatment of overactive bladder: a meta-analysis]. Jiang, XZ; Xu, C; Xu, ZS; Zhang, NZ; Zhao, HF, 2012)	0.38
" Combination therapy was well tolerated, and adverse events were consistent with the safety profiles of both compounds."	( Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Angulo, JC; Garcia-Hernandez, A; Haab, F; Katona, F; Klaver, M; Oelke, M; Traudtner, K; Van Kerrebroeck, P; Vik, V, 2013)	0.39
" Safety assessments included treatment-emergent adverse events (TEAEs), blood pressure, pulse rate, postvoid residual (PVR) volume, and laboratory and electrocardiography (ECG) parameters."	( Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Abrams, P; Kay, R; Kelleher, C; Martina, R; Newgreen, D; Paireddy, A; Rechberger, T; Ridder, A; Staskin, D; van Maanen, R, 2015)	0.42
" Treatment-emergent adverse events were reported in 499 (46."	( Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Chapple, C; Drake, MJ; Drogendijk, T; Klaver, M; Oelke, M; Sokol, R; Traudtner, K; Van Kerrebroeck, P, 2015)	0.42
" We also assessed postvoid residual, maximum urinary ﬂow rate, incidence of urinary retention (UR), adverse events."	( Efficacy and safety of solifenacin plus tamsulosin oral controlled absorption system in men with lower urinary tract symptoms: a meta-analysis. Guo, XL; Li, MC; Liu, JH; Wang, SG; Wang, T; Wang, ZY; Yang, J; Ye, ZQ, )	0.13
" Both solifenacin and tolterodine ER have similar therapeutic efficacies and adverse events."	( [Comparisons of therapeutic efficacy and safety of solifenacin versus tolterodine in patients with overactive bladder: a meta-analysis of outcomes]. Li, J; Li, P; Liu, B; Wang, Y; Wu, Y, 2014)	0.4
" Safety assessments included adverse events (AEs), laboratory tests, vital signs, 12-lead electrocardiogram, QT corrected for heart rate using Fridericia's correction (QTcF) interval and post-void residual (PVR) volume."	( Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). Gotoh, M; Hamada, T; Homma, Y; Igawa, Y; Kakizaki, H; Kobayashi, A; Kuroishi, K; Nishizawa, O; Okitsu, A; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M, 2015)	0.42
" Quality of life (QoL) was assessed using International Prostate Symptom Score and Overactive Bladder Symptom Score questionnaires and safety according to the incidence of adverse events."	( Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local estrogen for the treatment of overactive bladder in postmenopausal women--a multicenter, randomized, open-label, controlled comparison study. Bai, WP; Cheng, XX; Gong, MY; Huang, YL; Jiang, F; Li, HF; Li, X; Tong, XW; Wang, JJ; Xu, HC; Xu, T; Xu, XX; Zhu, L, 2016)	0.74
" The most common adverse event was dry mouth (19."	( Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local estrogen for the treatment of overactive bladder in postmenopausal women--a multicenter, randomized, open-label, controlled comparison study. Bai, WP; Cheng, XX; Gong, MY; Huang, YL; Jiang, F; Li, HF; Li, X; Tong, XW; Wang, JJ; Xu, HC; Xu, T; Xu, XX; Zhu, L, 2016)	0.74
"Solifenacin with or without local estrogen was effective and safe for overactive bladder treatment in postmenopausal women."	( Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local estrogen for the treatment of overactive bladder in postmenopausal women--a multicenter, randomized, open-label, controlled comparison study. Bai, WP; Cheng, XX; Gong, MY; Huang, YL; Jiang, F; Li, HF; Li, X; Tong, XW; Wang, JJ; Xu, HC; Xu, T; Xu, XX; Zhu, L, 2016)	0.74
" Adverse event were monitored and summarized."	( Efficacy and Safety of Gabapentin in Comparison to Solifenacin Succinate in Adult Overactive Bladder Treatment. Balingit, JC; Chua, ME; Esmeňa, EB; Morales, ML; See, MC, 2018)	0.73
" End points included a change from baseline in the number of urinary incontinence episodes per day and the proportion of patients with a 100% reduction (dry) in the number of incontinence episodes per day as co-primaries, other urinary symptoms and quality of life, all at week 12, and adverse events."	( The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial. Abrams, S; Aliotta, P; Everaert, K; Herschorn, S; Kohan, A; Lam, W; McCammon, K; Sriram, R, 2017)	0.46
" Safety assessments included incidence and frequency of treatment-emergent adverse events (TEAEs), post-void residual (PVR) urine volume, and changes from baseline in laboratory parameters."	( Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). Abrams, P; Arlandis, S; Chapple, CR; Herschorn, S; Lee, KS; Mitcheson, D; Paireddy, A; Ridder, A; Robinson, D; Stoelzel, M; van Maanen, R, 2017)	0.46
" CV safety assessments included frequency of CV-related treatment-emergent adverse events (TEAEs), change from baseline in vital signs (systolic blood pressure [SBP], diastolic blood pressure [DBP], pulse rate) and electrocardiogram (ECG) parameters."	( Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE). Athanasiou, S; Cambronero Santos, J; Chapple, CR; Drake, MJ; Esen, A; Herschorn, S; Huang, M; MacDiarmid, S; Mitcheson, D; Siddiqui, E; Stoelzel, M, 2017)	0.46
" Outcome measures included incidence and severity of adverse events (primary end point), laboratory variables, vital signs, 12-lead electrocardiogram, post-void residual volume, and change from baseline to end of treatment in mean number of micturitions and incontinence episodes per 24 hours, number of incontinence-free days per 7 days and number of grade 3 or 4 urgency episodes per 24 hours (adolescents only)."	( Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive Bladder. Besuyen, R; Bolduc, S; Bosman, B; Dahler, E; Hollestein-Havelaar, A; Newgreen, D; Rittig, S; Sawyer, W; Snijder, R, 2017)	0.46
" The incidence of drug related treatment emergent adverse events was 34."	( Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive Bladder. Besuyen, R; Bolduc, S; Bosman, B; Dahler, E; Hollestein-Havelaar, A; Newgreen, D; Rittig, S; Sawyer, W; Snijder, R, 2017)	0.46
"Once daily solifenacin oral suspension was well tolerated for up to 52 weeks in children 5 to less than 12 years old and adolescents 12 to less than 18 years old diagnosed with overactive bladder, with constipation and electrocardiogram QT prolonged as the most common adverse reactions, respectively."	( Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive Bladder. Besuyen, R; Bolduc, S; Bosman, B; Dahler, E; Hollestein-Havelaar, A; Newgreen, D; Rittig, S; Sawyer, W; Snijder, R, 2017)	0.46
"The primary objective was safety, measured as treatment-emergent adverse events (TEAEs)."	( Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Abrams, P; Al-Shukri, S; Chapple, C; Gratzke, C; Herschorn, S; Mueller, ER; Paireddy, A; Rechberger, T; Ridder, A; Robinson, D; Stoelzel, M; van Maanen, R; Yoon, SJ, 2018)	0.48
" With regard to drug-related treatment-emergent adverse events (DR-TEAEs) and dry mouth, mirabegron showed better tolerance than solifenacin."	( Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Cui, Y; Gao, Z; Li, Y; Wang, J; Wu, J; Yuan, H; Zhou, Z; Zhu, Z, 2019)	0.51
"The therapeutic effect of mirabegron is similar to that of solifenacin, and mirabegron does not increase the risk of adverse events (AEs)."	( Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Cui, Y; Gao, Z; Li, Y; Wang, J; Wu, J; Yuan, H; Zhou, Z; Zhu, Z, 2019)	0.51
" Safety assessments included treatment-emergent adverse events, vital signs, 12-lead electrocardiograms, post-void residual volume, and laboratory evaluations."	( Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study). Gotoh, M; Hamada, T; Homma, Y; Igawa, Y; Kakizaki, H; Kobayashi, A; Kuroishi, K; Nishizawa, O; Okitsu, A; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M, 2019)	0.51
"1% women, mean age 65 years) experienced at least one treatment-emergent adverse event, with similar rates for all treatments."	( Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study). Gotoh, M; Hamada, T; Homma, Y; Igawa, Y; Kakizaki, H; Kobayashi, A; Kuroishi, K; Nishizawa, O; Okitsu, A; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M, 2019)	0.51
" CV safety was assessed using treatment-emergent adverse events (TEAEs), vital signs, and 12-lead electrocardiograms (ECGs)."	( Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study. Hamada, T; Igawa, Y; Kato, D; Katoh, T; Kuroishi, K; Yamaguchi, O, 2020)	0.56
" Safety was evaluated using the proportion of treatment-emergent adverse events."	( Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. Cardozo, L; Chapple, CR; Choudhury, N; Cruz, F; Heesakkers, J; Herschorn, S; Siddiqui, E; Staskin, D; Stoelzel, M, 2020)	0.56
" However, the adverse systemic side-effects of oxybutynin, the most widely used agent, are of concern."	( Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies. Baka-Ostrowska, M; Bolong, D; Bosman, B; Dahler, E; Davies, LN; Franco, I; Hoebeke, P; Newgreen, D; Snijder, R; Stroosma, O; Vande Walle, J; Verheggen, F, 2020)	0.56
" Four and nine patients experienced constipation and thirst, respectively, and all adverse effects were graded as ≤2."	( Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study. Bang, WJ; Cho, JS; Cho, ST; Hyun, JS; Joo, KJ; Kim, BH; Kim, JK; Lee, JB; Lee, YS; Oh, CY; Seo, YJ; Shim, M, 2020)	0.56
"Standard dose antimuscarinic treatment using solifenacin (5 mg) may be a safe and effective treatment for patients with OAB symptoms refractory to low-dose antimuscarinic treatment."	( Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study. Bang, WJ; Cho, JS; Cho, ST; Hyun, JS; Joo, KJ; Kim, BH; Kim, JK; Lee, JB; Lee, YS; Oh, CY; Seo, YJ; Shim, M, 2020)	0.56
"The aim of this network meta-analysis was to determine the most efficacious oral antimuscarinic or β-adrenoceptor agonist accounting for adverse events for the management of IOAB."	( Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. Aydh, A; Carlin, GL; Grossmann, NC; Hajebrahimi, S; Jilch, S; Katayama, S; König, F; Laukhtina, E; Mori, K; Mostafaei, H; Pradere, B; Quhal, F; Rajwa, P; Roehrborn, CG; Salehi-Pourmehr, H; Sari Motlagh, R; Schuettfort, VM; Shariat, SF, 2022)	0.72
" Gastrointestinal problems, especially due to antimuscarinic agents, were the most prevalent adverse events."	( Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. Aydh, A; Carlin, GL; Grossmann, NC; Hajebrahimi, S; Jilch, S; Katayama, S; König, F; Laukhtina, E; Mori, K; Mostafaei, H; Pradere, B; Quhal, F; Rajwa, P; Roehrborn, CG; Salehi-Pourmehr, H; Sari Motlagh, R; Schuettfort, VM; Shariat, SF, 2022)	0.72
" Although finding the best medication for all is impossible, finding the best treatment for every individual patient can be done by considering the efficacy of a medicine for the most bothersome symptom(s) in balance with drug-specific adverse events."	( Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. Aydh, A; Carlin, GL; Grossmann, NC; Hajebrahimi, S; Jilch, S; Katayama, S; König, F; Laukhtina, E; Mori, K; Mostafaei, H; Pradere, B; Quhal, F; Rajwa, P; Roehrborn, CG; Salehi-Pourmehr, H; Sari Motlagh, R; Schuettfort, VM; Shariat, SF, 2022)	0.72
"This study aimed to find the most efficient oral medication to treat overactive bladder, taking into consideration the adverse events."	( Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. Aydh, A; Carlin, GL; Grossmann, NC; Hajebrahimi, S; Jilch, S; Katayama, S; König, F; Laukhtina, E; Mori, K; Mostafaei, H; Pradere, B; Quhal, F; Rajwa, P; Roehrborn, CG; Salehi-Pourmehr, H; Sari Motlagh, R; Schuettfort, VM; Shariat, SF, 2022)	0.72
"This cohort study evaluates therapeutic efficacy and adverse events (AEs) of various overactive bladder (OAB) medications for patients with central nervous system (CNS) disorders."	( Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders-A cohort study. Chen, SF; Chuang, YC; Kuo, HC; Liao, CH; Wang, CC, 2022)	0.72
" Still, concerns have been raised over the nervous system (NS) adverse drug events (AEs) due to their dissimilarities to muscarinic receptor-subtype affinities."	( Analysis of the nervous system and gastrointestinal adverse events associated with solifenacin in older adults using the US FDA adverse event reporting system. Chyou, TY; Nicholls, C; Nishtala, PS, 2023)	0.91
"This study aimed to identify the nervous system and gastrointestinal adverse drug events (ADEs) associated with solifenacin use in older adults (≥65 years)."	( Analysis of the nervous system and gastrointestinal adverse events associated with solifenacin in older adults using the US FDA adverse event reporting system. Chyou, TY; Nicholls, C; Nishtala, PS, 2023)	0.91
"A case/non-case analysis was performed on the reports submitted to the FDA Adverse Event Reporting System (FAERS) between 01/01/2004 and 30/06/2020."	( Analysis of the nervous system and gastrointestinal adverse events associated with solifenacin in older adults using the US FDA adverse event reporting system. Chyou, TY; Nicholls, C; Nishtala, PS, 2023)	0.91
" Aim of our study was to analyze real-life data of adverse events related to AMs and B3A reported on Eudra-Vigilance (EV) Database."	( Adverse events related to antimuscarinics and beta-3-agonist: "real-life" data from the Eudra-Vigilance Database. Cicione, A; DE Nunzio, C; DI Giacomo, F; Disabato, G; Franco, A; Gallo, G; Gravina, C; Lombardo, R; Nacchia, A; Rovesti, L; Trucchi, A; Tubaro, A; Turchi, B, 2022)	0.72
"EV database is the system for managing and analyzing information on suspected adverse reactions to medicines which have been authorized or being studied in clinical trials in the European Economic Area (EEA)."	( Adverse events related to antimuscarinics and beta-3-agonist: "real-life" data from the Eudra-Vigilance Database. Cicione, A; DE Nunzio, C; DI Giacomo, F; Disabato, G; Franco, A; Gallo, G; Gravina, C; Lombardo, R; Nacchia, A; Rovesti, L; Trucchi, A; Tubaro, A; Turchi, B, 2022)	0.72
" The incidence of drug-related adverse events in the solifenacin group was higher than that in the combination group, but there was no statistically significant difference (P > 0."	( Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study. Liu, YQ; Tang, QL; Tao, RZ; Wu, J; Zhou, S, 2022)	0.72

Excerpt	Reference	Relevance
"To determine the effect of food ingestion on the pharmacokinetic profile of solifenacin succinate (YM905; Vesicare, a new bladder selective muscarinic receptor antagonist for the treatment of overactive bladder, a chronic disease usually caused by involuntary detrusor muscle contractions during bladder filling."	( Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial. Krauwinkel, WJ; Mulder, H; Smulders, RA; Uchida, T, 2004)	0.55
" No statistically or clinically significant pharmacokinetic differences occurred between subjects in the fed and fasting states."	( Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial. Krauwinkel, WJ; Mulder, H; Smulders, RA; Uchida, T, 2004)	0.32
"The pharmacokinetic profile of solifenacin succinate (YM905; Vesicare), a new once-daily bladder-selective muscarinic receptor antagonist, was examined in 2 controlled trials of healthy young men."	( Pharmacokinetics and safety of solifenacin succinate in healthy young men. Huang, M; Krauwinkel, WJ; Smulders, RA; Swart, PJ, 2004)	0.9
" Secondary parameters included terminal elimination half-life (t1/2), time to C(max) (t(max)), fraction unbound, renal clearance, amount/percent of dose excreted in urine as solifenacin and its metabolites, and trough plasma metabolite concentrations."	( Effect of age on the pharmacokinetics of solifenacin in men and women. Krauwinkel, WJ; Mulder, H; Smulders, RA; Swart, PJ; Taekema-Roelvink, ME, 2005)	0.33
" In this study, no consistent safety/tolerability issues were associated with these pharmacokinetic differences and the administration of solifenacin 5 or 10 mg once daily was well tolerated."	( Effect of age on the pharmacokinetics of solifenacin in men and women. Krauwinkel, WJ; Mulder, H; Smulders, RA; Swart, PJ; Taekema-Roelvink, ME, 2005)	0.33
"The aim of this study was to evaluate the effect of solifenacin on the pharmacokinetic (PK) parameters of an oral contraceptive (OC) containing ethinyl estradiol (EE) and levonorgestrel (LNG)."	( Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study. Krauwinkel, WJ; Kuipers, ME; Smulders, RA; Swart, PJ; Taekema-Roelvink, ME; Visser, N, 2005)	0.33
" The potential for pharmacokinetic and/or pharmacodynamic interactions between solifenacin and warfarin or digoxin was investigated."	( Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects. Krauwinkel, WJ; Kuipers, ME; Smulders, RA, 2006)	0.33
" Pharmacokinetics was assessed using the standard measurements of maximum plasma concentration (Cmax), time to Cmax, area under the curve (AUC), and elimination half-life (t1/2)."	( Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers. Krauwinkel, WJ; Smith, NN; Smulders, RA; Swart, PJ, 2006)	0.33
" Blood and urine were collected for pharmacokinetic assessments."	( Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment. Hoon, T; Krauwinkel, W; Kuipers, M; Smulders, R, 2006)	0.33
" Pharmacokinetic parameters were assessed from blood samples drawn over a 360-h period."	( Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency. Hoon, TJ; Krauwinkel, WJ; Smith, NN; Smulders, RA, 2007)	0.34
" The terminal elimination half-life ranges from 33 to 85 hours, permitting once-daily administration."	( Clinical pharmacokinetics and pharmacodynamics of solifenacin. Doroshyenko, O; Fuhr, U, 2009)	0.35
"A pharmacokinetic bioequivalence study was conducted in Asian subjects, to compare a fixed dose combination capsule single oral dose of alpha adrenoceptor blocker-Alfuzosin hydrochloride 10mg extended release and muscarinic antagonists-Solifenacin succinate 5mg against individually administered Xatral XL 10mg tablets (Alfuzosin) of Sanofi Synthelabo Limited, United Kingdom (UK) and Vesicare 5mg tablets (Solifenacin) of Astellas Pharma Limited, UK under fed conditions."	( Combining benefits of an adrenergic and a muscarinic blocker in a single formulation - a pharmacokinetic evaluation. Arora, R; Arora, V; Dey, S; Kandhwal, K; Khuroo, AH; Madan, S; Monif, T; Nazarudheen, S; Reyar, S, 2013)	0.57

Excerpt	Reference	Relevance
"Randomized controlled trials evaluating solifenacin or its combination with tamsulosin for the treatment of SRSs were identified via a comprehensive search of Pubmed, Embase, Ovid, The Cochrane Library and relevant sources up to February 2017."	( The role of solifenacin, as monotherapy or combination with tamsulosin in ureteral stent-related symptoms: a systematic review and meta-analysis. Bai, B; Lei, Y; Mu, J; Wang, J; Zhang, T; Zhang, X, 2017)	0.46
"The aim of this study was to compare the efficacy of the transobturator tape (TOT) procedure combined with solifenacin (TOT-S) or prasterone (TOT-P) in postmenopausal women affected by mixed urinary incontinence (MUI) with a predominant stress urinary incontinence component."	( TOT in combination with solifenacin or intravaginal prasterone in postmenopausal women with mixed urinary incontinence: A retrospective analysis in 112 patients. Cardella, G; Grossi, G; Loggia, M; Morgani, C; Palazzetti, PL; Sala, F; Schiavi, MC; Valensise, HCC; Zullo, MA, 2023)	0.91

Excerpt	Reference	Relevance
" This study was designed to assess the absolute bioavailability of a single oral dose of solifenacin 10 mg, which is twice the suggested starting dose."	( Solifenacin demonstrates high absolute bioavailability in healthy men. Krauwinkel, WJ; Kuipers, ME; Mulder, H; Visser, N, 2004)	0.32
" A single oral dose of solifenacin 10 mg had a high absolute bioavailability of 88."	( Solifenacin demonstrates high absolute bioavailability in healthy men. Krauwinkel, WJ; Kuipers, ME; Mulder, H; Visser, N, 2004)	0.32
" This finding suggests that solifenacin may have a higher and less variable bioavailability than other antimuscarinic agents."	( Solifenacin demonstrates high absolute bioavailability in healthy men. Krauwinkel, WJ; Kuipers, ME; Mulder, H; Visser, N, 2004)	0.32
" Solifenacin has been shown to display selectivity for bladder versus salivary tissue in vitro, and studies in healthy men have shown that absorption is slow but extensive with an absolute bioavailability of 88%."	( Solifenacin in overactive bladder syndrome. Payne, CK, 2006)	0.33
" The validated method was successfully employed for bioavailability study after oral administration of 10 mg of alfuzosin hydrochloride and 5mg of solifenacin succinate tablet formulations in eight healthy volunteers under fed condition."	( Highly sensitive and rapid LC-ESI-MS/MS method for the simultaneous quantification of uroselective alpha1-blocker, alfuzosin and an antimuscarinic agent, solifenacin in human plasma. Jangid, AG; Mistri, HN; Pudage, A; Rathod, DM; Shrivastav, PS, 2008)	0.55
" Studies in healthy adults have shown that the drug has high absolute bioavailability of about 90%, which does not decrease with concomitant food intake."	( Clinical pharmacokinetics and pharmacodynamics of solifenacin. Doroshyenko, O; Fuhr, U, 2009)	0.35

Excerpt	Relevance	Reference
"To evaluate the dose-response relationship and safety/tolerability of solifenacin succinate (YM905) in the treatment of overactive bladder (OAB), and to compare its efficacy and safety/tolerability with tolterodine 2 mg twice daily."	( Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. Araño, P; Bosch, JL; Chapple, CR; De Ridder, D; Kramer, AE; Ridder, AM, 2004)	0.56
"To assess in a phase 3a trial the efficacy of solifenacin succinate, a once-daily oral antimuscarinic agent in development at 5-mg and 10-mg dosage strengths, for the treatment of overactive bladder (OAB) (Yamanouchi Pharmaceutical Co."	( Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Al-Shukri, S; Chapple, CR; Everaert, K; Huang, M; Meffan, P; Rechberger, T; Ridder, A, 2004)	0.58
" All patients who entered the open-label extension study initially received solifenacin 5 mg daily for 4 weeks, after which a flexible dosing regimen allowed patients to individualise their treatment (5 mg or 10 mg) at each of the 3 study visits."	( Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Cardozo, L; Chapple, C; Haab, F; Ridder, AM, 2005)	0.33
" Although the suppression induced by solifenacin was more persistent than that due to oxybutynin, the antagonistic effect of solifenacin on the dose-response curves to pilocarpine was significantly weaker than that of oxybutynin."	( Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice. Miyata, K; Oki, T; Sato, S; Yamada, S, 2005)	0.53
"Solifenacin, with a flexible dosing regimen, showed greater efficacy to tolterodine in decreasing urgency episodes, incontinence, urge incontinence and pad usage and increasing the volume voided per micturition."	( A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Bolodeoku, J; Chapple, CR; Drogendijk, T; Martinez-Garcia, R; Selvaggi, L; Toozs-Hobson, P; Warnack, W; Wright, DM, 2005)	0.58
"Solifenacin, with a flexible dosing regimen, was found to be superior to tolterodine ER with respect to the majority of the efficacy variables."	( A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Bolodeoku, J; Chapple, CR; Drogendijk, T; Martinez-Garcia, R; Selvaggi, L; Toozs-Hobson, P; Warnack, W; Wright, DM, 2005)	0.58
" Subjects received warfarin on the 10th day of 16 days of dosing with either solifenacin or placebo."	( Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects. Krauwinkel, WJ; Kuipers, ME; Smulders, RA, 2006)	0.33
"Since the pharmacokinetics and pharmacodynamics of a single dose of warfarin and the steady-state pharmacokinetics of digoxin were not affected by coadministration of solifenacin in healthy subjects, the need for dosing adjustments for digoxin and/or warfarin does not seem warranted."	( Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects. Krauwinkel, WJ; Kuipers, ME; Smulders, RA, 2006)	0.33
" Solifenacin demonstrates a favourable tolerability profile, with mild dry mouth as the most common adverse event associated with its use, both at the 5- and 10-mg doses; this allows for flexibility in the dosing regimen, in which physicians can administer solifenacin 5 mg, with the option to safely increase the dose to 10 mg if necessary based on the severity of patient's symptoms."	( Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder. Chapple, CR, 2006)	0.33
"Flexibly dosed solifenacin 5 and 10 mg QD was associated with reductions in patient-reported OAB symptom bother and improvements in patients' perception of bladder condition and HRQOL."	( Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Andoh, M; Garely, AD; Kaufman, JM; Sand, PK; Smith, N, 2006)	0.33
" All patients were started on solifenacin 5 mg/day; at week 4, the dosage could be increased to 10 mg/day and at week 8 could be maintained or decreased back to 5 mg/day."	( Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes. Garely, AD; Lucente, V; Smith, N; Vapnek, J, 2007)	0.34
"Patients reporting urge incontinence as their most bothersome OAB symptom can be expected to demonstrate significant improvements in multiple patient-related outcomes following treatment with flexibly dosed solifenacin."	( Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes. Garely, AD; Lucente, V; Smith, N; Vapnek, J, 2007)	0.34
"In the 12 week, VESIcare Open-Label Trial (VOLT), patients received solifenacin 5 mg or 10 mg once daily according to an individualized, flexible dosing regimen."	( Solifenacin treatment for overactive bladder in black patients: patient-reported symptom bother and health-related quality of life outcomes. Burks, D; Garely, AD; Mallett, V; Smith, N, 2007)	0.34
" This article summarizes the efficacy, contraindications, precautions, dosing and common side effects of these agents."	( Pharmacologic management of overactive bladder. Hilas, O; Lam, S, 2007)	0.34
"A 1-year Markov model was constructed using data from a 12-week, randomised, double-blind study that compared flexible dosing with solifenacin (5 mg and 10 mg) with tolterodine (IR 2 mg bd/ER 4 mg) in adults with OAB."	( A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Bolodeoku, J; Khullar, V; Mundy, A; Odeyemi, I; Speakman, M, 2008)	0.35
"Flexible dosing with solifenacin is likely to be cost-effective versus tolterodine in the treatment of OAB."	( A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Bolodeoku, J; Khullar, V; Mundy, A; Odeyemi, I; Speakman, M, 2008)	0.35
" Once-daily, flexible dosing with this agent provides 24-hour control of OAB symptoms and significantly increases warning time (the period from onset of urgency to voiding), which may also increase a patient's chance of avoiding episodes of incontinence."	( Solifenacin at 3 years: a review of efficacy and safety. Capo, JP; Forero-Schwanhaeuser, S; Pelman, RS, 2008)	0.35
" Patients were treated with solifenacin 5 mg or solifenacin 10 mg in the flexible dosing regimen."	( [Efficacy and safety of solifenacin in daily clinical practice--clinical study phase IV]. Fabisovský, M; Havránek, O; Krhut, J; Míka, D; Valis, P, 2008)	0.35
"The purpose of the present analysis was to analyze and compare the cost-effectiveness of solifenacin flexible dosing (5-10 mg) with tolterodine 4 mg sustained release (SR) or placebo (assumed to be comparable to no treatment) for patients with overactive bladder (OAB) symptoms."	( Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. Axelsen, S; Kulseng-Hansen, S; Mattiasson, A; Milsom, I; Nilsson, CG; Wickstrøm, J, 2009)	0.35
"Solifenacin flexible dosing was more effective with respect to reducing OAB symptoms compared to both placebo and tolterodine 4 mg."	( Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. Axelsen, S; Kulseng-Hansen, S; Mattiasson, A; Milsom, I; Nilsson, CG; Wickstrøm, J, 2009)	0.35
"Solifenacin flexible dosing was a cost-effective treatment alternative compared to tolterodine 4 mg SR."	( Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. Axelsen, S; Kulseng-Hansen, S; Mattiasson, A; Milsom, I; Nilsson, CG; Wickstrøm, J, 2009)	0.35
"In this 12-week multicenter trial, 739 patients (aged >or= 18 years) were randomized to flexibly dosed solifenacin (5/10 mg) or placebo."	( Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Andoh, M; Forero-Schwanhaeuser, S; Karram, MM; Laramée, C; Nandy, IM; Seifeldin, R; Serels, SR; Toglia, MR, 2009)	0.35
"In VIBRANT, a double-blind, US-based trial, patients with OAB for > or = 3 months received flexibly dosed solifenacin or placebo for 12 weeks."	( Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. Forero-Schwanhaeuser, S; He, W; Marshall, TS; Mitcheson, HD; Samuels, TA; Vardy, MD; Wegenke, JD, 2009)	0.35
"As early as week 4 and through EOT, flexibly dosed solifenacin significantly improved OAB symptom bother and HRQL as well as the symptoms of urgency, frequency and incontinence compared with placebo."	( Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. Forero-Schwanhaeuser, S; He, W; Marshall, TS; Mitcheson, HD; Samuels, TA; Vardy, MD; Wegenke, JD, 2009)	0.35
"Subjects with OAB for > or =3 months received flexibly dosed solifenacin for 12 weeks."	( Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes. Andoh, M; Forero-Schwanhaeuser, S; Gittelman, M; Goldfischer, ER; Kaplan, SA; Steers, WD, 2010)	0.36
" After a washout period of > or = 14 days, patients began treatment with solifenacin 5 mg/d with dosing adjustments allowed at week 4 (to 10 mg/d) and at week 8 (back to 5 mg/d for patients whose dose was increased to 10 mg/d at week 4)."	( Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis. Marshall, T; Noe, L; Rasouliyan, L; Runken, MC; Seifeldin, R; Zinner, N, 2009)	0.35
"In this large group of older patients, flexibly dosed solifenacin was associated with reductions in diary-documented OAB symptoms (VERSUS)."	( Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: post-hoc analysis of 2 open-label studies. Capo', JP; Forero-Schwanhaeuser, S; He, W; Lucente, V, 2011)	0.37
" Studies have found that a flexible dosing strategy can be effective in improving OAB symptoms with minimal impact on tolerability."	( Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). Amarenco, G; Cardozo, L; Compion, G; Drogendijk, T; Mikulas, J; Pushkar, D; Wright, M, 2013)	0.39
" Patients who requested a dose increase at week 8 generally had more severe OAB symptoms at baseline and a smaller response at week 8 to the initial solifenacin 5 mg dosage than those who did not."	( Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). Amarenco, G; Cardozo, L; Compion, G; Drogendijk, T; Mikulas, J; Pushkar, D; Wright, M, 2013)	0.39
"To evaluate cognitive effects during chronic stable dosing with solifenacin and oxybutynin versus placebo in older (≥75 yr) subjects with MCI."	( Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Compion, G; Dale, M; Stow, B; Tretter, R; Wagg, A, 2013)	0.39
"05 for the dose-response slope, all variables)."	( Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Angulo, JC; Garcia-Hernandez, A; Haab, F; Katona, F; Klaver, M; Oelke, M; Traudtner, K; Van Kerrebroeck, P; Vik, V, 2013)	0.39
" The secondary objective was to explore the dose-response relationship and the safety/tolerability compared with placebo and monotherapy."	( Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Abrams, P; Kay, R; Kelleher, C; Martina, R; Newgreen, D; Paireddy, A; Rechberger, T; Ridder, A; Staskin, D; van Maanen, R, 2015)	0.42
"To evaluate long-term (up to 52 wk) safety and efficacy of flexible dosing of two fixed-dose combinations (FDC) of Soli plus TOCAS in men with moderate to severe storage symptoms and voiding symptoms."	( Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Chapple, C; Drake, MJ; Drogendijk, T; Klaver, M; Oelke, M; Sokol, R; Traudtner, K; Van Kerrebroeck, P, 2015)	0.42
" During the treatment all patients, except for those who were assigned to the control group, received Loop Diuretic Furosemide dosed at 20-30 mg per day and Solifenacin dosed at 5 mg per day (First comparison group) and 10 mg per day (Second comparison group)."	( Decrease of risk of developing symptoms of OAB in elderly men and women treated with loop diuretic for hypertensive disease using solifenacin. Ivanovskaya, MA; Kosilov, KV; Kosilova, LV; Loparev, SA, 2014)	0.4
"2%), group of the patients treated with Furosemide and standard- dosed (11."	( Decrease of risk of developing symptoms of OAB in elderly men and women treated with loop diuretic for hypertensive disease using solifenacin. Ivanovskaya, MA; Kosilov, KV; Kosilova, LV; Loparev, SA, 2014)	0.4
" Administration of low dosed Solifenacin is sufficient for significant decrease in risk of developing symptoms of overactive bladder."	( Decrease of risk of developing symptoms of OAB in elderly men and women treated with loop diuretic for hypertensive disease using solifenacin. Ivanovskaya, MA; Kosilov, KV; Kosilova, LV; Loparev, SA, 2014)	0.4
"We evaluated changes in urinary nerve growth factor (NGF) and NGF/creatinine (NGF/Cr) levels after increasing the dosage of solifenacin in overactive bladder patients."	( Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder. Cekmen, MB; Ciftci, S; Ozkurkcugil, C; Ustuner, M; Yavuz, U; Yilmaz, H; Yuksekkaya, M, 2016)	0.43
" After increasing the dosage of solifenacin to 10 mg in group 2, the NGF and NGF/Cr levels decreased to normal levels."	( Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder. Cekmen, MB; Ciftci, S; Ozkurkcugil, C; Ustuner, M; Yavuz, U; Yilmaz, H; Yuksekkaya, M, 2016)	0.43
"0% changed the dosage (84."	( Profile of oab patient on treatment with flexible-dose antimuscarinic drugs in daily clinical practice. Arumi, D; García-Mediero, JM; Lizarraga, I; Sánchez-Ballester, F; Sobrón-Bustamante, M, 2016)	0.43
"We compared changes in nocturia and sleep-related parameters between daytime and nighttime solifenacin dosing in patents with overactive bladder (OAB) and nocturia."	( Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality. Cho, WY; Choi, S; Kwon, T; Lee, JZ; Min, K; Moon, KH; Oh, TH, 2017)	0.46
"The combination of solifenacin in a double dosage along with tamsulosin can be recommended for elderly benign prostatic hyperplasia patients with overactive bladder symptoms."	( Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage. Gainullina, Y; Kosilov, K; Kosilova, L; Kuzina, I; Kuznetsov, V; Loparev, S; Prokofyeva, A, 2018)	0.48
" We also found that increasing value of total payment and increasing frequency of payments were both independently associated with increased odds of prescribing with a dose-response effect."	( The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. Chang, SL; Dupree, JM; Kirk, PS; Modi, PK; Singer, EA; Wang, Y, 2018)	0.48
" Thus, overall sexual function in men with BPH and severe LUTS is not impaired by prolonged intake of double dosage of solifenacin combined with dutasteride."	( The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin. Gainullina, Y; Karashchuk, E; Kosilov, K; Kosilova, L; Kuzina, I; Kuznetsov, V; Loparev, S; Prokofyeva, A, 2018)	0.48
" In the case-time-control design, we made separate analyses to evaluate the dose-response risk of delirium."	( Risk of delirium associated with antimuscarinics in older adults: A case-time-control study. Chyou, TY; Nishtala, PS, 2022)	0.72
" The dose-response risk of delirium was significant for oxybutynin (0."	( Risk of delirium associated with antimuscarinics in older adults: A case-time-control study. Chyou, TY; Nishtala, PS, 2022)	0.72
" The work was also extended to verify content uniformity of dosage units in accordance with USP recommendations."	( State-of-the-art mathematically induced filtration approaches for smart spectrophotometric assessment of silodosin and solifenacin mixture in their new challenging formulation: Multi-tool greenness and whiteness evaluation. Abdel-Moety, EM; Marzouk, HM; Rezk, MR; Rostom, Y; Wadie, M, 2024)	1.44

Class	Description
isoquinolines	A class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Muscarinic acetylcholine receptor M2	Homo sapiens (human)	IC50 (µMol)	0.5737	0.0000	1.2326	7.7930	AID598150
Muscarinic acetylcholine receptor M1	Homo sapiens (human)	IC50 (µMol)	0.0635	0.0000	1.4039	10.0000	AID598151
Muscarinic acetylcholine receptor M3	Homo sapiens (human)	IC50 (µMol)	0.1308	0.0001	1.0104	9.9280	AID598149
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
regulation of heart contraction	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
response to virus	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
positive regulation of monoatomic ion transport	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
neuromuscular synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of locomotion	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
saliva secretion	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
cognition	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of postsynaptic membrane potential	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of glial cell proliferation	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
positive regulation of intracellular protein transport	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
calcium-mediated signaling	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
synaptic transmission, cholinergic	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
positive regulation of insulin secretion	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
protein modification process	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
positive regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
saliva secretion	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
ligand-gated ion channel signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
arrestin family protein binding	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
signaling receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
acetylcholine binding	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
asymmetric synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
symmetric synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
presynaptic membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
neuronal cell body	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
axon terminus	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
glutamatergic synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
cholinergic synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
presynaptic membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
axon terminus	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
postsynaptic density membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
glutamatergic synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
cholinergic synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
endoplasmic reticulum membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
basal plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
basolateral plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID598151	Displacement of [3H]NMS from human muscarinic M1 receptor expressed in CHO-K1 cells after 1 hr by scintillation counting	2011	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11	Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl carbamates as potent and long acting muscarinic antagonists.
AID598150	Displacement of [3H]NMS from human muscarinic M2 receptor expressed in CHO-K1 cells after 1 hr by scintillation counting	2011	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11	Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl carbamates as potent and long acting muscarinic antagonists.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID598149	Displacement of [3H]NMS from human muscarinic M3 receptor expressed in CHO-K1 cells after 1 hr by scintillation counting	2011	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11	Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl carbamates as potent and long acting muscarinic antagonists.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID598152	Selectivity ratio of IC50 for human muscarinic M2 receptor to IC50 for human muscarinic M3 receptor	2011	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11	Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl carbamates as potent and long acting muscarinic antagonists.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID598153	Selectivity ratio of IC50 for human muscarinic M1 receptor to IC50 for human muscarinic M3 receptor	2011	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11	Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl carbamates as potent and long acting muscarinic antagonists.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	122 (25.21)	29.6817
2010's	281 (58.06)	24.3611
2020's	81 (16.74)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	194 (37.16%)	5.53%
Reviews	80 (15.33%)	6.00%
Case Studies	13 (2.49%)	4.05%
Observational	19 (3.64%)	0.25%
Other	216 (41.38%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (136)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
"A Randomized, Placebo-Controlled Parallel-Design Trial of the Effect of Solifenacin Treatment for Overactive Bladder in Women With Anterior Vaginal Wall Prolapse Managed With a Pessary (the PESSARY Study)" [NCT01092624]	Phase 4	94 participants (Anticipated)	Interventional	2010-03-31	Terminated(stopped due to sponsor closed study due to poor enrollment)
Effect of Electroacupuncture for Women With Urgency-predominant Mixed Urinary Incontinence: a Three Armed Non-inferior Randomized Controlled Trial [NCT03787654]		282 participants (Anticipated)	Interventional	2019-03-01	Recruiting
A Therapeutic Exploratory Clinical Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder [NCT03566134]	Phase 2	306 participants (Actual)	Interventional	2018-07-10	Completed
A Multicenter, Open-label, Single Ascending Dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Patients Aged 5 to 17 Years (Inclusive) With Overactive Bladder (OAB) [NCT01262391]	Phase 1	42 participants (Actual)	Interventional	2010-10-20	Completed
Comparative Study of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After Transurethral Resection of the Prostate - A Randomized Prospective Study [NCT03632772]	Phase 2	130 participants (Anticipated)	Interventional	2018-08-01	Recruiting
Comparison of Solifenacin Combined With Pelvic Floor Muscle and Whole Body Vibration Training With Solifenacin Alone in Patients With Overactive Bladder Syndrome. - A Prospective Randomized Parallel Group Trial [NCT01314781]	Phase 4	66 participants (Actual)	Interventional	2012-01-31	Completed
Czech Observational Study to Evaluate Quality of Life in Patients Switched to Vesicare™ (Solifenacin) From Other Antimuscarinics [NCT02087098]		2,000 participants (Actual)	Observational	2014-06-30	Completed
A Phase 1 Study to Evaluate the Effect of Steady State Solifenacin and Mirabegron on the Steady State Pharmacokinetics of Digoxin in Healthy Subjects [NCT02127034]	Phase 1	26 participants (Actual)	Interventional	2014-03-31	Completed
Reproducibility Study of OABSS and Its Response to Solifenacin Treatment (RESORT) and Validity in Korean Populations; Part 2: Responsiveness and Validity [NCT01318837]	Phase 4	100 participants (Actual)	Interventional	2010-04-30	Completed
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania [NCT03602508]		5,589 participants (Actual)	Observational	2018-07-20	Completed
An Open-label, One-sequence, Two-arm Study to Evaluate the Effect of Steady State Concentrations of Mirabegron on the Pharmacokinetics of Solifenacin and to Evaluate the Effect of Steady State Concentrations of Solifenacin on the Pharmacokinetics of Mirab [NCT01297192]	Phase 1	41 participants (Actual)	Interventional	2009-03-31	Completed
Pharmacokinetic Drug Interaction Between Solifenacin 10mg and Tamsulosin 0.4mg in Healthy Male Volunteers [NCT02180997]	Phase 1	36 participants (Actual)	Interventional	2014-07-31	Completed
Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation: Prospective Randomized Controlled Trial [NCT05490082]	Phase 3	100 participants (Anticipated)	Interventional	2022-03-01	Recruiting
Efficacy of of Pelvic Floor Muscle Training( PFMT ) With Surface Electromyographic Biofeedback and Medication in Women With Overactive Bladder [NCT04477265]		140 participants (Actual)	Interventional	2016-06-16	Completed
Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve (T-PTNS) for Solifenacin 10 mg. in the Treatment of Hyperactive Bladder Syndrome: no Inferiority Phase IV Randomized Clinical Trial [NCT03468465]	Phase 4	110 participants (Anticipated)	Interventional	2018-05-04	Active, not recruiting
Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome [NCT05040984]		500 participants (Anticipated)	Observational	2021-04-30	Recruiting
Reproducibility Study of OABSS and Its Response to Treatment in Indonesia - Part 2: Responsiveness [NCT01122563]		55 participants (Actual)	Observational	2009-09-30	Completed
Higher Neural and Cognitive Changes Following Anticholinergic Versus Beta 3 Agonist Versus Placebo Treatments in Female Patients With Overactive Bladder: a Multicenter Randomized Controlled Pilot Trial [NCT03817931]	Phase 4	30 participants (Anticipated)	Interventional	2019-08-05	Recruiting
A Double Blind, Randomized Placebo Controlled Trial of the Perioperative Use of Solifenacin in the Management of Postoperative Overactive Bladder Symptoms in Patients With Mixed Incontinence Undergoing Suburethral Sling Procedures. [NCT00852696]		1 participants (Actual)	Interventional	2008-02-29	Terminated(stopped due to Investigator left Cleveland Clinic and absolutely no data is available.)
A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and Urinary Nerve Growth Factor in Female Subjects With Overactive Bladder and a Diagnosis of Detrusor Overactivity - A Double-blind, Randomised, Placebo-controll [NCT01093534]	Phase 4	547 participants (Actual)	Interventional	2010-01-31	Completed
Medication Effects on Periurethral Sensation, Urethral Sphincter Activity and Pressure Flow Parameters [NCT01028014]		56 participants (Actual)	Interventional	2010-04-30	Completed
URGE-PD: A Multi-site, Double-blind, Randomized, Placebo Controlled Trial of Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease [NCT01018264]	Phase 4	23 participants (Actual)	Interventional	2010-01-31	Completed
A Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi-center Study of Fixed Dose Combinations of Solifenacin Succinate (6 mg and 9 mg) With Tamsulosin Hydrochloride OCAS 0.4 mg and Tamsulosin Hydrochloride OCAS 0.4 mg Monotherapy, in Male [NCT01018511]	Phase 3	1,334 participants (Actual)	Interventional	2010-01-31	Completed
A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With [NCT00629642]	Phase 4	249 participants (Actual)	Interventional	2008-03-14	Completed
An Open-label, Parallel Group, Randomized, Two-way Crossover, Multiple Dose Study to Compare the Pharmacokinetic Profiles of Solifenacin Succinate and Tamsulosin HCl Following Co-administration of Single Entity Tablets and Administration of Three Differen [NCT02634489]	Phase 1	46 participants (Actual)	Interventional	2009-03-31	Completed
Validation of a Real-time Urodynamic Measure of Urinary Urgency as a Measure of the Success of Drug Treatment [NCT00909428]	Phase 4	51 participants (Actual)	Interventional	2007-01-31	Completed
Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia : a Randomized, Double Blinded, Parallel Design, Active Controlled, Multi-center [NCT02827578]	Phase 3	588 participants (Anticipated)	Interventional	2016-01-31	Recruiting
A Phase 1 Study to Evaluate the Effect of Steady State Solifenacin and Mirabegron on the Steady State Pharmacokinetics of Tamsulosin HCl in Healthy Male Subjects [NCT02169713]	Phase 1	20 participants (Actual)	Interventional	2014-05-31	Completed
Efficacy and Safety of Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder [NCT03558919]	Phase 4	81 participants (Actual)	Interventional	2017-01-01	Completed
The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Symptomatic Non-complicated Urinary Tract Infection in Females [NCT02094703]	Phase 4	126 participants (Anticipated)	Interventional	2013-04-30	Recruiting
A Prospective, Non-interventional, Registry Study of Patients Initiating Pharmacologic Therapy for Overactive Bladder in Taiwan, Korea and China [NCT03572231]		805 participants (Actual)	Observational	2018-07-19	Completed
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease [NCT03149809]	Phase 3	77 participants (Actual)	Interventional	2018-03-01	Completed
Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics [NCT04090190]	Phase 4	20 participants (Actual)	Interventional	2019-10-30	Completed
Phase 2a Exploratory, Randomized, Double-blind, Parallel-group Study of ONO-8577 Compared to Combination of Solifenacin Succinate/ Mirabegron for Overactive Bladder [NCT03106623]	Phase 2	207 participants (Actual)	Interventional	2017-04-07	Completed
Comparison of the Effect of Flexible Dosage of Solifenacin Succinate Between Patients Who Have Frequent Micturition With and Without Urgency [NCT00979472]	Phase 4	291 participants (Actual)	Interventional	2009-04-30	Completed
Solifenacin in a Flexible Dose Regimen With Tolterodine as an Active Comparator in a Double-blind, Double-dummy, Randomised Overactive Bladder Symptom Trial [NCT00802373]	Phase 3	1,355 participants (Actual)	Interventional	2003-07-31	Completed
Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes: A Prospective Randomized Controlled Trial [NCT02540707]	Phase 4	113 participants (Actual)	Interventional	2015-09-08	Completed
Impact of Solifenacin Succinate for Treatment of Acute Irritative Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer [NCT02805452]	Phase 3	4 participants (Actual)	Interventional	2016-07-31	Terminated(stopped due to Target of recruitment not reachable)
Efficacy of Low-intensity Shock Wave Therapy on Persistent Storage Symptoms After Transurethral Surgery for Benign Prostatic Obstruction: A Randomized Controlled Trial [NCT04437108]		132 participants (Actual)	Interventional	2020-07-04	Completed
An Open-label, Randomized, Parallel Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms [NCT02715024]	Phase 4	52 participants (Actual)	Interventional	2007-09-30	Completed
A Multicenter, Double-blind, Placebo-controlled and Active-reference, Randomized, Parallel, Therapeutic Confirmatory Clinical Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder [NCT05282069]	Phase 3	607 participants (Actual)	Interventional	2022-05-12	Active, not recruiting
Overactive Bladder Symptom Scores (OABSS) Responsiveness Before and After Anticholinergic Treatment in Women With Overactive Bladder (OAB) [NCT02667470]	Phase 4	50 participants (Actual)	Interventional	2009-09-30	Completed
Persistence of Solifenacin Treatment in Overactive Bladder Patients in Real Life Practice: A 12-month, Prospective, Multicenter, Open-label, Observational Study [NCT00985387]		1,215 participants (Actual)	Observational	2009-08-31	Completed
A Phase 1, Open-Label, Randomized, Single Dose, 3-Way Crossover Study to Address the Relative Bioavailability of Solifenacin Liquid Suspension 10mg (Fed and Fasting) Versus the VESIcare (Solifenacin Succinate) 10 mg Tablet (Fasting) in Healthy Volunteers [NCT01015040]	Phase 1	24 participants (Actual)	Interventional	2009-09-30	Completed
A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Dose Study To Investigate The Effects Of 8 Mg Fesoterodine SR Tablets And 10 Mg Solifenacin Tablet On Gastrointestinal Transit In Healthy Female Subjects. [NCT00832650]	Phase 1	60 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to Protocol A0221057 was terminated on December 25, 2009 for futility. There were no safety concerns related to this decision.)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Solifenacin Succinate as Add-on Therapy for Overactive Bladder (OAB) Symptoms in Men Treated for Benign Prostatic Hyperplasia (BPH) With Tamsulosin Hydrochloride [NCT00771394]	Phase 4	638 participants (Actual)	Interventional	2008-10-31	Completed
Recurrence of Symptoms of Overactive Bladder After Weaning Versus Sudden Stopping of Anticholinergics [NCT04064619]		60 participants (Actual)	Interventional	2018-01-01	Completed
A Prospective, Open-label, Observational, Multi-center Study for the Identification of Predictive Factors for the Solifenacin Treatment in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks and Evaluation of Efficacy and Persist [NCT00884104]	Phase 4	307 participants (Actual)	Interventional	2009-03-31	Completed
Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)for the Treatment of Clinically Significant Benign Prostate Hyperplasia (BPH) [NCT00826527]	Phase 4	23 participants (Anticipated)	Interventional	2007-01-31	Recruiting
A Randomized, Double Blind, Placebo-Controlled, Parallel Group Comparison of the Efficacy and Safety of Any Alpha Blocker Monotherapy and Any Alpha Blocker Plus Solifenacin in Men With Residual Overactive Bladder Symptoms of Urinary Frequency and Urgency [NCT00699049]	Phase 4	94 participants (Actual)	Interventional	2008-06-30	Completed
A Phase 1, Open-Label, Randomized, Single Dose, 3-Way Crossover Study to Assess the Relative Bioavailability of Solifenacin Liquid Suspension 10 mg (Formulation B) Versus Solifenacin Liquid Suspension 10 mg (Formulation A) and to Assess the Relative Bioav [NCT01406158]	Phase 1	24 participants (Actual)	Interventional	2011-05-31	Completed
Randomized Double Blinded Placebo-controlled Trial of the Once Daily 5mg Dose of Solifenacin Succinate vs. Placebo in Inner City Women Ages 20-45 With Overactive Bladder [NCT00773552]	Phase 4	0 participants (Actual)	Interventional	2008-11-30	Withdrawn(stopped due to Investigator Left Institution)
A Randomized Clinical Trial Comparing Alpha Blacker (Tamsulosin) and Anticholinergic (Solifenacin) in Treatment of Ureteral Stent Related Symptoms [NCT01880619]	Phase 4	131 participants (Actual)	Interventional	2013-01-31	Completed
Solifenacin in the Treatment of Urgency Symptoms of Overactive Bladder in a Rising Dose, Randomized, Placebo-controlled, Double-blind Trial [NCT00801944]	Phase 3	973 participants (Actual)	Interventional	2004-04-30	Completed
To Explore the Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and Develop Its Urinary Biomarker [NCT04693897]		400 participants (Anticipated)	Observational [Patient Registry]	2021-03-01	Not yet recruiting
A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Safety of the Co-administration of Solifenacin Succinate With 0.4 mg Tamsulosin Hydrochloride OCAS (TOCAS) Using Urodynamics in Male Subjects With [NCT00507455]	Phase 2	222 participants (Actual)	Interventional	2007-06-30	Completed
Comparisons of Urodynamic Effects, Urinary Nerve Growth Factor Levels and Outcomes in Female Overactive Bladder Patients After 3-month Versus 6-month Solifenacin Treatment: a Randomized Prospective Study [NCT01876186]	Phase 4	200 participants (Anticipated)	Interventional	2013-05-31	Recruiting
A Phase 1, Open-label, One-sequence Study to Assess the Effect of Verapamil on the Steady State Pharmacokinetics of Solifenacin and Tamsulosin Administered as a Combination Tablet EC905 in Healthy Male Subjects. [NCT01943487]	Phase 1	36 participants (Actual)	Interventional	2009-08-31	Completed
An Open-label, Randomized, Two-way Crossover, Multiple Dose Study to Evaluate the Steady State Pharmacokinetics of the Two Final Combination Tablet Formulations (EC905; Tamsulosin HCl/ Solifenacin Succinate; 0.4 mg/6 mg and 0.4 mg/9 mg) in Healthy Male Vo [NCT01953848]	Phase 1	27 participants (Actual)	Interventional	2010-04-30	Completed
An Open-label, Randomized, Three-period Crossover, Single Dose Study to Compare the Pharmacokinetics of the Final EC905 Formulation to Marketed Solifenacin (Vesicare®) and Tamsulosin OCAS (Omnic OCAS®) [NCT01953887]	Phase 1	30 participants (Actual)	Interventional	2010-03-31	Completed
Evaluation of the Efficacy and Urodynamic Outcomes Between Intradetrusor onabotulinumtoxinA Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity [NCT05968885]	Phase 4	300 participants (Anticipated)	Interventional	2021-10-01	Recruiting
An Open-label, Parallel Group, Randomized, Two-sequence, Three-way Crossover Study to Assess the Relative Bioavailability of Solifenacin Succinate and Mirabegron Fixed-dose Combination Tablets Compared to Co-administration of Single Entity Tablets at Thre [NCT02010944]	Phase 1	72 participants (Actual)	Interventional	2012-09-30	Completed
A Randomized, Open-label, Single Dose, 2-way Crossover Study to Compare the Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers [NCT02940314]	Phase 1	36 participants (Actual)	Interventional	2016-03-31	Completed
[NCT00584090]	Phase 4	0 participants (Actual)	Interventional	2007-11-30	Withdrawn(stopped due to Study withdrawn with intent of persuing larger, multi-site study.)
A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron [NCT01340027]	Phase 2	1,307 participants (Actual)	Interventional	2011-03-29	Completed
An Open-label, Long Term, Multi-center Study to Assess the Safety and Efficacy of Fixed Dose Combinations of Solifenacin Succinate (6 mg and 9 mg) With Tamsulosin Hydrochloride OCAS 0.4 mg, in Male Subjects With Lower Urinary Tract Symptoms (LUTS) Associa [NCT01021332]	Phase 3	1,067 participants (Actual)	Interventional	2010-04-26	Completed
Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence [NCT01166438]	Phase 3	249 participants (Actual)	Interventional	2010-03-31	Completed
A Study to Compare the Cognitive Effect of Solifenacin 5mg Once-daily and Oxybutynin 5mg Twice-daily After Chronic Dosing Versus Placebo in Subjects 75 Years and Over With Mild Cognitive Impairment - A Double-blind, Randomized, Multi-center Study [NCT01126424]	Phase 4	26 participants (Actual)	Interventional	2010-04-30	Completed
Vesicare™ (Solifenacin) in the Treatment of Urinary Incontinence After Radical Prostatectomy [NCT01215721]		40 participants (Actual)	Interventional	2010-10-31	Completed
Comparison of Oxybutynin and Solifenacin in the Treatment of Overactive Bladder: a Randomized Controlled Multicenter Trial [NCT01423838]	Phase 4	500 participants (Anticipated)	Interventional	2011-09-30	Not yet recruiting
Solifenacin Succinate in a Flexible Dose Regimen With Simplified Bladder Training Versus Solifenacin Succinate in a Flexible Dose Regimen Alone in a Prospective, Randomized, Parallel Group, Overactive Bladder Symptom Study [NCT00337558]	Phase 4	643 participants (Actual)	Interventional	2006-05-31	Completed
A Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi Center Dose Ranging Study of Solifenacin Succinate in Combination With Tamsulosin Hydrochloride Compared With Solifenacin Succinate Monotherapy and Tamsulosin Hydrochloride Monotherapy [NCT00510406]	Phase 2	919 participants (Actual)	Interventional	2007-01-31	Completed
[NCT00189800]	Phase 3	0 participants	Interventional		Completed
Efficacy and Safety of High Dose Vitamin D Supplementation for Overactive Bladder Dry in Children: A Randomized Clinical Trial [NCT05709990]		300 participants (Anticipated)	Interventional	2023-01-15	Recruiting
Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms: a Randomized Controlled Trial [NCT04325880]	Phase 3	240 participants (Anticipated)	Interventional	2021-12-01	Recruiting
Efficacy and Safety of Gabapentin in Treating Overactive Bladder [NCT01486706]	Phase 2/Phase 3	94 participants (Actual)	Interventional	2010-10-31	Completed
Specified Drug Use Results Survey of Vesicare Tablets [NCT01489709]		1,160 participants (Actual)	Observational	2010-06-30	Completed
An Open-Label Multicenter Study to Assess the Efficacy and Safety of Daily Oral Administration of 5 and 10mg VESIcare® (Solifenacin Succinate) in Patients Who Wish to Switch From Detrol LA® (Tolterodine Tartrate Extended Release) for the Treatment of Over [NCT00454740]	Phase 3	441 participants (Actual)	Interventional	2004-06-30	Completed
[NCT00441428]		0 participants	Observational	2006-02-28	Completed
An Open-label Study of the Efficacy and Safety of 5 and 10mg VESIcare® (Solifenacin Succinate) in Patients With Overactive Bladder Symptoms VOLT: VESIcare® Open-Label Trial [NCT00463541]	Phase 3	2,225 participants (Actual)	Interventional	2004-06-30	Completed
Solifenacin Succinate vs. Fesoterodine A Comparison Trial for the Treatment of Bothersome Urgency Symptoms [NCT01595152]		60 participants (Anticipated)	Interventional	2012-05-31	Recruiting
Multi-site, Randomized, Opened and Controlled Comparison Study on the Effectiveness and Safety of Solifenacin Succinate Tablets and Solifenacin Succinate Tablets + Estrogen for Overactive Bladder in the Post-menopausal Women [NCT01833663]	Phase 4	200 participants (Anticipated)	Interventional	2011-10-31	Completed
A Randomized, Double-Blind, Paralleled, Active Controlled, Multi-Center Study of the Efficacy and Safety of 5mg Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder [NCT00368706]	Phase 3	246 participants (Actual)	Interventional	2006-09-30	Completed
An Open Label Randomized, Single Dose, Three-way, Partial Replicate Bioequivalence Study to Determine the Bioequivalence of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg F [NCT05767632]	Phase 1	30 participants (Actual)	Interventional	2022-05-30	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Safety and Efficacy, Phase 4 Study of VESIcare® (Solifenacin Succinate) or Placebo in Combination With Tamsulosin HCl for the Treatment of Residual OAB Symptoms of Urgency and Fre [NCT00333112]	Phase 4	398 participants (Actual)	Interventional	2006-05-31	Completed
A Prospective Randomized Trial of Behavioral Modification and Solifenacin (Vesicare)vs Solifenacin (Vesicare) Alone for the Treatment of Urge Incontinence in Patients With an Overactive Bladder [NCT00821184]	Phase 3	12 participants (Actual)	Interventional	2006-09-30	Terminated(stopped due to Insufficient subject availability/findings for data analysis)
A Prospective Randomized Controlled Trial: Comparison of the Transcutaneous Posterior Tibial Nerve Stimulation and Oral Solifenacin Treatments' Effects in Women Between 18-80 Years Old Who Have Overactive Bladder [NCT06024005]		34 participants (Actual)	Interventional	2023-04-18	Completed
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Daily Oral Administration of 5mg and 10mg VESIcare® for the Treatment of Urgency Associated With Overactive Bladder [NCT00454896]	Phase 3	739 participants (Actual)	Interventional	2004-05-31	Completed
A Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase 4, Multicenter Study to Assess Efficacy and Safety of VESIcare® (Solifenacin Succinate) to Improve Urinary Continence of Subjects After Robotic Assisted Radical Prostatectomy [NCT01371994]	Phase 4	640 participants (Actual)	Interventional	2011-08-02	Completed
The Therapeutic Effect of Beta-3 Agonist and Anti-muscarinic Agent on Overactive Bladder Among Sjogren's Syndrome Patient [NCT04909255]	Phase 4	50 participants (Anticipated)	Interventional	2021-03-23	Recruiting
Efficacy of Tadalafil and Solifenacin Versus Tamsulosin and Solifenacin Combination Therapy for the Treatment of Benign Prostatic Hyperplasia With Overactive Bladder: A Randomized Controlled Trial [NCT05494567]	Phase 4	60 participants (Anticipated)	Interventional	2021-11-08	Active, not recruiting
A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects From 5 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) [NCT01539707]	Phase 1	14 participants (Actual)	Interventional	2012-03-13	Completed
Clinical Trial to Compare the Efficacy and Safety of Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia [NCT02972268]	Phase 3	780 participants (Actual)	Interventional	2016-02-01	Completed
VECTOR: A Randomized Double-blind Study to Assess the Safety and Efficacy of Solifenacin (Vesicare®) in Comparison to Oxybutynin for Overactive Bladder Patients [NCT00431041]	Phase 4	132 participants (Actual)	Interventional	2006-12-31	Completed
Injections of Botulinum Toxin A or Anticholinergic Treatment as First Line Therapy to Treat Neurogenic Overactive Bladder in Patients With Multiple Sclerosis [NCT04819360]	Phase 4	46 participants (Anticipated)	Interventional	2021-06-01	Recruiting
Effect of Electroacupuncture Versus PFMT Plus Solifenacin for Moderate and Severe Mixed Urinary Incontinence in Female: a Multicenter, Noninferiority, Randomized Controlled Trial [NCT02047032]		500 participants (Actual)	Interventional	2014-04-30	Completed
Urinary NGF, PGE2 and ATP: Potential Biomarkers for Diagnosis and Prediction of Treatment Efficacy in Overactive Bladder Patients [NCT01499069]		191 participants (Actual)	Interventional	2010-02-28	Completed
Studies of Psychiatric Predisposing Factors, Treatment-related Cardiovascular Effects, and Prognostic Factors Associated With Antimuscarinic Drug (Tolterodine) for Female Overactive Bladder Syndrome [NCT01503580]		155 participants (Actual)	Interventional	2008-08-31	Completed
A Prospective, Open Label, Single Arm, Multicenter Study to Estimate the Efficacy and Safety of Solifenacin in Female With Clinically Significant Stress Urinary Incontinence and Urgency Urinary Incontinence [NCT01505439]	Phase 4	311 participants (Actual)	Interventional	2011-06-30	Completed
Post-treatment Normallized Urodynamic Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug and Its Correlations With Voiding Diary, King's Health Questionnaire, and Overactive Bladder Sympt [NCT01627145]		300 participants (Anticipated)	Interventional	2012-08-31	Recruiting
An Irish Observational Study to Evaluate LUTS Storage Symptom Improvement in Men Being Treated With Vesitirim™ (Solifenacin) [NCT01639794]		12 participants (Actual)	Observational	2012-02-29	Completed
"Feasibility of At-home Titration of Solifenacin 5 and 10mg and Effect on Symptoms and Quality of Life in a Typical OAB Population" [NCT00759577]	Phase 4	36 participants (Actual)	Interventional	2008-09-30	Terminated(stopped due to difficulty with enrollment)
Surgical vs. Medical Treatment of Urge Urinary Incontinence in Women [NCT01737411]	Phase 1/Phase 2	120 participants (Anticipated)	Interventional	2013-01-31	Recruiting
Phase 1/2 Study of the Effect of TOT or Solifenacin After Cesa or Vasa on Urge Urinary Incontinence [NCT01737918]	Phase 1/Phase 2	120 participants (Anticipated)	Interventional	2013-01-31	Recruiting
A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Solifenacin and Percutaneous Tibial Nerve Stimulation in Patients With Refractory Overactive Bladder [NCT01764893]	Phase 4	8 participants (Actual)	Interventional	2013-01-31	Terminated(stopped due to Enrolling too slowly due to insurance plans no longer covering the cost of the Percutaneous Tibial Nerve Stimulation treatment.)
A Phase II Randomized Study of Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients Receiving Adjuvant Hormonal Therapy [NCT01530373]	Phase 2	6 participants (Actual)	Interventional	2012-02-29	Active, not recruiting
A Pilot Study to Assess the Safety and Efficacy of Solifenacin (VESIcare) for Improving Urinary and Bladder Functions in Patients Undergoing Radiation Therapy of the Prostate [NCT01777217]	Phase 4	8 participants (Actual)	Interventional	2013-02-28	Terminated(stopped due to Terminated)
A Phase 3, Open-Label, Baseline-controlled, Multicenter, Sequential Dose Titration Study to Assess the Long-Term Efficacy and Safety, and the Pharmacokinetics of Solifenacin Succinate Suspension in Patients From 5 to Less Than 18 Years of Age With Neuroge [NCT01565694]	Phase 3	76 participants (Actual)	Interventional	2012-08-14	Completed
A Prospective, Multicenter, Observation Study to Estimate the Dry Mouth in OAB Patients With Solifenacin [NCT01437670]		262 participants (Actual)	Observational	2011-09-30	Completed
Electroacupuncture Versus Solifenacin Succinate for Female Overactive Bladder: A Multicenter, Randomized, Controlled, Noninferiority Trial [NCT05798403]		204 participants (Anticipated)	Interventional	2023-07-07	Recruiting
Comparisons of the Impact of Beta-3 Agonist Versus Antimuscarinics on Psychological Distress, Sexual Function, Bladder Wall Thickness and Blood Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study. [NCT04023253]	Phase 3	120 participants (Anticipated)	Interventional	2019-08-01	Recruiting
Safety and Efficacy Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children, a Randomized Clinical Trial [NCT05240456]	Phase 1/Phase 2	70 participants (Anticipated)	Interventional	2022-02-28	Not yet recruiting
A Phase II, Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type [NCT02549196]	Phase 2	28 participants (Actual)	Interventional	2015-10-07	Completed
Comparison of the Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With OAB: A Prospective Randomized Multicenter Study [NCT01533597]	Phase 4	70 participants (Actual)	Interventional	2010-12-31	Completed
A Randomized, Double-blind, Placebo-controlled, Parallel-group, and Phase IV Study of Efficacy and Safety of Solifenacin Succinate in Patients With Overactive Bladder After TURP or PVP [NCT01747577]	Phase 4	68 participants (Actual)	Interventional	2012-12-04	Completed
A Phase 3, Double-Blind, Randomized, Multi-center, Placebo-Controlled Sequential Dose Titration Study to Assess Efficacy, Safety and Population Pharmacokinetics of Solifenacin Succinate Suspension in Pediatric Subjects From 5 to Less Than 18 Years of Age [NCT01565707]	Phase 3	189 participants (Actual)	Interventional	2012-06-07	Completed
Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms (LUTS) Post Ureteroscopy for Stone Management [NCT01381120]	Phase 4	84 participants (Actual)	Interventional	2010-10-31	Completed
A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subject [NCT02045862]	Phase 3	1,829 participants (Actual)	Interventional	2014-03-17	Completed
Efficacy and Safety of Intradetrusor BOTOX Injection Combined With Percutaneous Tibial Nerve Stimulation for Managing Children With Overactive Bladder Not Responding to Monotherapy [NCT05911594]		128 participants (Actual)	Interventional	2022-02-14	Completed
A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy [NCT01638000]	Phase 3	1,887 participants (Actual)	Interventional	2012-06-12	Completed
Incontinence & Intimate Partners: Assessing the Contribution of Treatment [NCT01559389]	Phase 4	138 participants (Actual)	Interventional	2012-03-09	Completed
The Effect of Solifenacin on Post Void Dribbling in Women: A Randomized Controlled Multicenter Trial [NCT01470001]		118 participants (Actual)	Interventional	2011-11-30	Completed
The Effectiveness, Superiority and Safety of EA on OAB:Multi-center Randomized Controlled Trial [NCT02452879]		180 participants (Anticipated)	Interventional	2014-10-31	Recruiting
A Phase 3, Open-Label, Baseline-controlled, Multi-center, Sequential Dose-Titration Study to Assess the Pharmacokinetics, Long-Term Efficacy and Safety of Solifenacin Succinate Suspension in Children From 6 Months to Less Than 5 Years of Age With Neurogen [NCT01981954]	Phase 3	23 participants (Actual)	Interventional	2013-09-25	Completed
Vesicare™ (Solifenacin) in the Treatment of Urinary Incontinence After Radical Prostatectomy [NCT00581061]		13 participants (Actual)	Interventional	2008-06-30	Terminated(stopped due to Study subjects were not compliant with study protocols.)
Urinary Nerve Growth Factor as a Biomarker for Medical Treatment of Male Lower Urinary Tract Symptoms: A Pilot Trial [NCT01457573]	Phase 4	10 participants (Actual)	Interventional	2011-10-31	Completed
A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms [NCT01908829]	Phase 3	2,174 participants (Actual)	Interventional	2013-07-10	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 4, Multi-center Study of VESIcare® (Solifenacin Succinate) in Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life VIBRANT: VESIcare® Investig [NCT00573508]	Phase 4	768 participants (Actual)	Interventional	2007-08-31	Completed
Belgian Observational Study to Evaluate Storage and Voiding Symptoms Improvement in Male Subjects With Lower Urinary Tract Predominant Storage Symptoms (Overactive Bladder Syndrome) Being Treated With Solifenacin in Monotherapy or Combination [NCT01799902]		86 participants (Actual)	Observational	2011-12-31	Completed
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monot [NCT01972841]	Phase 3	3,527 participants (Actual)	Interventional	2013-11-05	Completed
[NCT01767519]	Phase 3	356 participants (Actual)	Interventional	2013-03-01	Completed
Safety and Efficacy of Mirabegron as Add-on Therapy in Patients With Overactive Bladder Treated With Solifenacin: A Postmarketing Open-label Study in Japan [NCT01745094]	Phase 4	223 participants (Actual)	Interventional	2012-10-01	Completed
Clinical Trial to Investigate and Compare the Pharmacokinetic Characteristics and Safety/Tolerability After Single Administration of JLP-1207 and Soifenacin/Tamsulosin in Healthy Male Volunteers. [NCT02494349]	Phase 1	54 participants (Actual)	Interventional	2015-08-31	Completed
An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects With Overactive Bladder (OAB) [NCT01655069]	Phase 3	148 participants (Actual)	Interventional	2012-10-04	Completed
The Effect of Short Term Solifenacin for Overactive Bladder on the Female Urinary Microbiome [NCT01642277]	Phase 2	134 participants (Actual)	Interventional	2012-07-31	Completed
Postmarketing Study of Mirabegron in Japan: Long-term Add-on Therapy With Antimuscarinics in Patients With Overactive Bladder Treated With Mirabegron [NCT02294396]	Phase 4	649 participants (Actual)	Interventional	2014-10-28	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00431041 (4) [back to overview]	Change From Baseline in Urgency Episodes as Reported in Subject 3-day Diary
NCT00431041 (4) [back to overview]	The Number of Subjects Reporting Incidence of Dry Mouth as an Adverse Event
NCT00431041 (4) [back to overview]	Change From Baseline in Micturition Frequency as Reported in Subject 3-day Diary
NCT00431041 (4) [back to overview]	The Severity of Dry Mouth Reported as an Adverse Event
NCT00507455 (18) [back to overview]	Change From Baseline in IPSS Storage Score
NCT00507455 (18) [back to overview]	Change From Baseline in IPSS Voiding Score
NCT00507455 (18) [back to overview]	Change From Baseline in Number of Incontinence Episodes Per 24 Hours
NCT00507455 (18) [back to overview]	Change From Baseline in Number of Micturitions Per 24 Hours
NCT00507455 (18) [back to overview]	Change From Baseline in Number of Urgency Episodes Per 24 Hours
NCT00507455 (18) [back to overview]	Change From Baseline in Patient Perception of Bladder Condition (PPBC)
NCT00507455 (18) [back to overview]	Change From Baseline in Post Void Residual Volume (PVR)
NCT00507455 (18) [back to overview]	Change From Baseline in Volume Voided Per Micturition
NCT00507455 (18) [back to overview]	Safety Assessed by Adverse Events (AEs), Electrocardiogram (ECG), Vital Signs, Physical Exam and Laboratory Tests
NCT00507455 (18) [back to overview]	Change From Baseline in ICIQ-MLUTS Total Symptom Bother Score
NCT00507455 (18) [back to overview]	Change From Baseline in ICIQ-LUTSqol Overall Symptom Interference of Life Score
NCT00507455 (18) [back to overview]	Change From Baseline to End of Treatment in Percent Bladder Voiding Efficiency (BVE)
NCT00507455 (18) [back to overview]	Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax)
NCT00507455 (18) [back to overview]	Change From Baseline to End of Treatment in Detrusor Pressure at Maximum Flow Rate (PdetQmax)
NCT00507455 (18) [back to overview]	Change From Baseline to End of Treatment in Bladder Contractility Index (BCI)
NCT00507455 (18) [back to overview]	Change From Baseline in International Prostate Symptoms Score (IPSS)
NCT00507455 (18) [back to overview]	Change From Baseline in International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptom (ICIQ MLUTS) Total Symptom Score
NCT00507455 (18) [back to overview]	Change From Baseline in International Consultation on Incontinence Questionnaire - Lower Urinary Tract Symptom Quality of Life (ICIQ-LUTSqol) Symptom Score
NCT00573508 (13) [back to overview]	Change From Baseline to Each Visit in Symptom Bother Utilizing the OAB-q Score
NCT00573508 (13) [back to overview]	Change From Baseline to Each Visit in the OAB-q HRQL Sub-domain Scores of Coping, Concern, Sleep and Social
NCT00573508 (13) [back to overview]	Change From Baseline in International Consultation on Incontinence Modular Questionnaire Male Sexual Matters Associated With Lower Urinary Tract Symptoms (ICIQ-MLUTSsex) Overall Symptom and Bother Scores.
NCT00573508 (13) [back to overview]	Change From Baseline to End of Treatment in Overactive Bladder Questionnairre (OAB-q) Symptom Bother Score
NCT00573508 (13) [back to overview]	Number of Participants With Change From Baseline in the Global Assessment Score of the Patient Perception of Bladder Condition (PPBC)
NCT00573508 (13) [back to overview]	Patient Perception of Treatment Benefit at the End of Treatment in the Global Assessment Score of the Benefit, Satisfaction, and Willingness (BSW) Questionnaire
NCT00573508 (13) [back to overview]	Change From Baseline in International Consultation on Incontinence Modular Questionnaire Female Sexual Matters Associated With Lower Urinary Tract Symptoms (ICIQ-FLUTSsex)Overall Symptom and Bother Scores.
NCT00573508 (13) [back to overview]	Change From Baseline in the MCUI Behavior Therapy Stratified
NCT00573508 (13) [back to overview]	Change From Baseline in the Medical Care Use Index (MCUI) Medical Resource Utilization in the Past 3 Months
NCT00573508 (13) [back to overview]	Change From Baseline in the Treatment Satisfaction Visual Analog Scale (TS-VAS)
NCT00573508 (13) [back to overview]	Change From Baseline to Each Visit in OAB-q Health Related Quality of Life (HRQL) Total Score
NCT00573508 (13) [back to overview]	Change From Baseline in Work Productivity Assessment Index (WPAI)
NCT00573508 (13) [back to overview]	Change From Baseline to End of Treatment in Mean Parameters Per 24 Hours Recorded in 3-day Diary
NCT00581061 (3) [back to overview]	Compliance
NCT00581061 (3) [back to overview]	Side Effects
NCT00581061 (3) [back to overview]	Time to Continence
NCT00821184 (1) [back to overview]	Change From Baseline in the Number of Incontinence Episodes Per 24 Hours Measured by Voiding Diaries.
NCT00832650 (9) [back to overview]	Mean Proportion of Bowel Movements With Satisfaction Per Day
NCT00832650 (9) [back to overview]	Average Score of Ease of Passage During Defecation Per Day
NCT00832650 (9) [back to overview]	Colonic Filling at 6 Hours
NCT00832650 (9) [back to overview]	Colonic Transit at 24 Hours
NCT00832650 (9) [back to overview]	Colonic Transit at 48 Hours
NCT00832650 (9) [back to overview]	Mean Number of Stools Per Day
NCT00832650 (9) [back to overview]	Mean Score of Stool Consistency Per Day
NCT00832650 (9) [back to overview]	Proximal Colonic Emptying Time
NCT00832650 (9) [back to overview]	Time to Gastric Emptying
NCT00909428 (1) [back to overview]	Change in Maximal Cystometric Capacity (mL)
NCT01018264 (5) [back to overview]	Number of Urinary Incontinence Episodes Per 24 Hour Period
NCT01018264 (5) [back to overview]	Number of Micturations Per 24 Hour Period
NCT01018264 (5) [back to overview]	Number of Nocturia Episodes Per 24 Hour Period
NCT01018264 (5) [back to overview]	Parkinson's Disease Quality of Life Scale (PDQOL)
NCT01018264 (5) [back to overview]	Unified Parkinson's Disease Rating Scale (UPDRS) Total
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Total International Prostate Symptom Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Total Urgency Frequency Score (TUFS, Previously Known as Total Urgency Score [TUS])
NCT01018511 (44) [back to overview]	Percentage of Participants Who Were OAB-q Responders at End of Treatment
NCT01018511 (44) [back to overview]	Apparent Clearance (CL/F) of Tamsulosin
NCT01018511 (44) [back to overview]	Area Under the Curve at Steady State (AUCss) of Tamsulosin
NCT01018511 (44) [back to overview]	AUCss of Solifenacin
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Anxiety/Depression Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Mobility Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Pain/Discomfort Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Self-care Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Usual Activities Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Individual IPSS Scores
NCT01018511 (44) [back to overview]	CL/F of Solifenacin
NCT01018511 (44) [back to overview]	Clinician Global Impression Scale at End of Treatment: Overall Bladder Symptoms
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Visual Analogue Scale (VAS) Score
NCT01018511 (44) [back to overview]	Cminss of Solifenacin
NCT01018511 (44) [back to overview]	Maximum Concentration at Steady State (Cmaxss) of Tamsulosin
NCT01018511 (44) [back to overview]	Minimum Concentration at Steady State (Cminss) of Tamsulosin
NCT01018511 (44) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Pads Used Per 24 Hours
NCT01018511 (44) [back to overview]	Patient Global Impression Scale at End of Treatment: Overall Bladder Symptoms
NCT01018511 (44) [back to overview]	Time of Maximum Concentration at Steady State (Tmaxss) of Tamsulosin
NCT01018511 (44) [back to overview]	Tmaxss of Solifenacin
NCT01018511 (44) [back to overview]	Patient Global Impression Scale at End of Treatment: General Health
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Nocturia Episodes Per 24 Hours
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Micturitions Per 24 Hours
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Average Flow Rate (Qmean)
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Health Related QoL (HRQoL) Subscale: Coping Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in HRQoL Subscale: Concern Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in HRQoL Subscale: Sleep Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Urgency Episodes (PPIUS Grade 3 or 4) Per 24 Hours
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Mean Voided Volume Per Micturition
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Post Void Residual (PVR) Volume
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Symptom Bother Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours
NCT01018511 (44) [back to overview]	Cmaxss of Solifenacin
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax)
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in IPSS Voiding Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in IPSS Storage Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in IPSS QoL Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in HRQoL Subscale: Total Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in HRQoL Subscale: Social Score
NCT01018511 (44) [back to overview]	Change From Baseline to End of Treatment in Maximum Volume Voided Per Micturition
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in IPSS Quality of Life (QoL) Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in IPSS Storage Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax)
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Maximum Volume Voided Per Micturition
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Micturitions Per 24 Hours
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Pads Used Per 24 Hours
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Urgency Episodes (PPIUS Grade 3 or 4) Per 24 Hours
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Mean Voided Volume Per Micturition
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Post Void Residual (PVR) Volume
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Symptom Bother Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Total International Prostate Symptom Score (IPSS)
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Total Urgency Frequency Score (TUFS) (Previously Known as Total Urgency Score [TUS])
NCT01021332 (31) [back to overview]	Number of OAB-q Responders Based on Health-related Quality of Life: Total Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Anxiety/Depression Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Mobility Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Pain/Discomfort Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Self-care Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Usual Activities Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Individual IPSS Scores
NCT01021332 (31) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in IPSS Voiding Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Nocturia Episodes Per 24 Hours
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Average Flow Rate (Qmean)
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in EQ-5D Visual Analogue Scale (VAS) Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Concern Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Coping Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Sleep Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Social Score
NCT01021332 (31) [back to overview]	Change From Baseline to End of Treatment in Health-related Quality of Life (HRQoL) Subscale: Total Score
NCT01028014 (3) [back to overview]	Difference (Pre - Post) in Maximum Urine Flow Rate (Qmax) (Milliliters Per Second) as Measured by Pressure Flowmetry
NCT01028014 (3) [back to overview]	Difference (Pre - Post) in Urethral Sensation (Milliamps) as Measured by Current Perception Threshold Testing.
NCT01028014 (3) [back to overview]	Difference (Pre - Post) in Amplitude (Microvolts) of Urethral Sphincter Activity as Measured by Quantitative Concentric Needle EMG
NCT01093534 (25) [back to overview]	Change From Baseline in Patient Assessment of Treatment Satisfaction
NCT01093534 (25) [back to overview]	Change From Baseline in Patient Assessment of Urgency Bother
NCT01093534 (25) [back to overview]	Change From Baseline in Patient Perception of Bladder Condition (PPBC)
NCT01093534 (25) [back to overview]	Change From Baseline in Symptom Bother Score
NCT01093534 (25) [back to overview]	Change From Baseline to Week 12 in Bladder Wall Thickness
NCT01093534 (25) [back to overview]	Change From Baseline to Week 12 in Brain Derived Neurotrophic Factor Normalized by Urine Creatinine (uBDNF/Cr)
NCT01093534 (25) [back to overview]	Change From Baseline to Week 12 in Mean Level of Urgency
NCT01093534 (25) [back to overview]	Change From Baseline to Week 12 in Mean Number of Events (Micturitions Plus Incontinence Episodes) Per 24 Hours
NCT01093534 (25) [back to overview]	Change From Baseline to Week 12 in Mean Number of Incontinence Episodes Per 24 Hours
NCT01093534 (25) [back to overview]	Change From Baseline to Week 12 in Mean Number of Micturitions Per 24 Hours
NCT01093534 (25) [back to overview]	Change From Baseline to Week 12 in Mean Number of Urgency Events Per 24 Hours
NCT01093534 (25) [back to overview]	Change From Baseline to Week 12 in Mean Number of Urgency Micturitions Per 24 Hours
NCT01093534 (25) [back to overview]	Change From Baseline to Week 12 in Total Urgency Score
NCT01093534 (25) [back to overview]	Change From Baseline to Week 12 in Total Urinary Nerve Growth Factor Normalized by Urine Creatinine
NCT01093534 (25) [back to overview]	Neutralized Urinary Nerve Growth Factor Normalized by Urine Creatinine at Week 12
NCT01093534 (25) [back to overview]	Total Urinary Nerve Growth Factor Normalized by Urine Creatinine at Week 12
NCT01093534 (25) [back to overview]	Change From Baseline in Health-Related Quality of Life (HRQL)
NCT01093534 (25) [back to overview]	Change From Baseline to Week 6 and Week 12 in Bladder Wall Thickness
NCT01093534 (25) [back to overview]	Change From Baseline to Week 6 and Week 12 in Neutralized Urinary Nerve Growth Factor Normalized by Urine Creatinine
NCT01093534 (25) [back to overview]	Brain Derived Neurotrophic Factor Normalized by Urine Creatinine (uBDNF/Cr) at Week 12
NCT01093534 (25) [back to overview]	Change From Baseline in EuroQoL 5-Dimension Questionnaire Visual Analog Scale
NCT01093534 (25) [back to overview]	Percentage of Participants With Improvement or Deterioration in Patient Perception of Bladder Condition (PPBC)
NCT01093534 (25) [back to overview]	Change From Baseline in Mean Number of Urgency Incontinence Episodes With PPIUS Grade 3 or 4 Per 24 Hours
NCT01093534 (25) [back to overview]	Change From Baseline in Mean Number of Urgency Incontinence Episodes With PPIUS Grade 4 Per 24 Hours
NCT01093534 (25) [back to overview]	Percentage of Participants With Improvement and Worsening on the 5 Dimensions of the EQ-5D
NCT01126424 (6) [back to overview]	Change From Baseline in Cognitive Function Composite Score - Power of Attention
NCT01126424 (6) [back to overview]	Change From Baseline in Cognitive Function Composite Score - Quality of Episodic Secondary Memory
NCT01126424 (6) [back to overview]	Change From Baseline in Cognitive Function Composite Score - Quality of Working Memory
NCT01126424 (6) [back to overview]	Change From Baseline in Cognitive Function Composite Score - Speed of Memory
NCT01126424 (6) [back to overview]	Change From Baseline in Postural Stability Test
NCT01126424 (6) [back to overview]	Change From Baseline in Cognitive Function Composite Score - Continuity of Attention
NCT01166438 (5) [back to overview]	Change From Baseline in Score on OABq-SF
NCT01166438 (5) [back to overview]	Change in PFDI-SF and PFIQ-SF Total Scores
NCT01166438 (5) [back to overview]	Change in Urge Urinary Incontinence (UUI) Episodes
NCT01166438 (5) [back to overview]	Efficacy
NCT01166438 (5) [back to overview]	Patient Global Impression of Improvement
NCT01215721 (1) [back to overview]	Time to Continence
NCT01340027 (30) [back to overview]	Percentage of Participants With a Micturition Response
NCT01340027 (30) [back to overview]	Percentage of Participants With Zero Incontinence Episodes Post-baseline
NCT01340027 (30) [back to overview]	Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Pain/Discomfort Score
NCT01340027 (30) [back to overview]	Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Self-care Score
NCT01340027 (30) [back to overview]	Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Usual Activities Score
NCT01340027 (30) [back to overview]	Change From Baseline to Each Visit in Mean Level of Urgency
NCT01340027 (30) [back to overview]	Change From Baseline to Each Visit in Mean Number of Incontinence Episodes Per 24 Hours
NCT01340027 (30) [back to overview]	Change From Baseline to Each Visit in Mean Number of Micturitions Per 24 Hours
NCT01340027 (30) [back to overview]	Change From Baseline to Each Visit in Mean Number of Nocturia Episodes Per 24-Hours
NCT01340027 (30) [back to overview]	Change From Baseline to Each Visit in Mean Number of Pads Used Per 24 Hours
NCT01340027 (30) [back to overview]	Change From Baseline to Each Visit in Mean Number of Urgency Episodes (Grade 3 and/or 4) Per 24 Hours
NCT01340027 (30) [back to overview]	Change From Baseline to Each Visit in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT01340027 (30) [back to overview]	Change From Baseline to Each Visit in Mean Volume Voided Per Micturition
NCT01340027 (30) [back to overview]	Change From Baseline to End of Treatment in Work Productivity and Activity Impairment (WPAI)
NCT01340027 (30) [back to overview]	Percentage of Participants With 50% Reduction in Incontinence Episodes
NCT01340027 (30) [back to overview]	Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Anxiety/Depression Score
NCT01340027 (30) [back to overview]	Percentage of Participants With Major Improvement in PPBC
NCT01340027 (30) [back to overview]	Percentage of Participants With Improvement in PPBC
NCT01340027 (30) [back to overview]	Percentage of Participants With Deterioration in PPBC
NCT01340027 (30) [back to overview]	Percentage of Participants With a Symptom Bother Response
NCT01340027 (30) [back to overview]	Percentage of Participants With a Health-related Quality of Life Total Score Response
NCT01340027 (30) [back to overview]	Change From Baseline to End of Treatment in Treatment Satisfaction on Visual Analog Scale (TS-VAS)
NCT01340027 (30) [back to overview]	Change From Baseline to End of Treatment in Symptom Bother Score as Assessed by the Overactive Bladder Questionnaire (OAB-q)
NCT01340027 (30) [back to overview]	Change From Baseline to End of Treatment in Patient Perception of Bladder Condition (PPBC)
NCT01340027 (30) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Micturitions Per 24 Hours
NCT01340027 (30) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours
NCT01340027 (30) [back to overview]	Change From Baseline to End of Treatment in Health-related Quality of Life (HRQL) Total Score
NCT01340027 (30) [back to overview]	Change From Baseline to End of Treatment in European Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS)
NCT01340027 (30) [back to overview]	Change From Baseline to End of Treatment (EOT) in Mean Volume Voided Per Micturition
NCT01340027 (30) [back to overview]	Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Mobility Score
NCT01371994 (19) [back to overview]	Percentage of Participants Who Gain Continence During 12-week Treatment Period
NCT01371994 (19) [back to overview]	Baseline Work Productivity and Activity Impairment (WPAI): Percent Overall Work Impairment
NCT01371994 (19) [back to overview]	Baseline Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed
NCT01371994 (19) [back to overview]	International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) QOL Score at Baseline
NCT01371994 (19) [back to overview]	Time From Baseline to First Day of Returning to Work
NCT01371994 (19) [back to overview]	Change From Baseline in American Urology Association Quality of Life (QOL) Score
NCT01371994 (19) [back to overview]	Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Overall Work Impairment
NCT01371994 (19) [back to overview]	Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Activity Impairment
NCT01371994 (19) [back to overview]	Change From Baseline in International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) QOL Score
NCT01371994 (19) [back to overview]	Change From Baseline in Average Daily Pad Usage
NCT01371994 (19) [back to overview]	Change From Baseline in American Urology Association Symptom Score (AUASS)
NCT01371994 (19) [back to overview]	American Urology Association Symptom Score (AUASS) at Baseline
NCT01371994 (19) [back to overview]	Time From First Dose to Urinary Continence
NCT01371994 (19) [back to overview]	Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed
NCT01371994 (19) [back to overview]	Baseline Work Productivity and Activity Impairment (WPAI): Percent Impairment While Working
NCT01371994 (19) [back to overview]	Baseline Work Productivity and Activity Impairment (WPAI): Percent Activity Impairment
NCT01371994 (19) [back to overview]	Average Daily Pad Usage at Baseline
NCT01371994 (19) [back to overview]	American Urology Association Quality of Life (QOL) Score at Baseline
NCT01371994 (19) [back to overview]	Change From Baseline in Work Productivity Assessment Index (WPAI): Percent Impairment While Working
NCT01381120 (2) [back to overview]	Change in Post-ureteroscopy Stent-induced Pain
NCT01381120 (2) [back to overview]	Change in Post-ureteroscopy Stent-induced Lower Urinary Tract Symptoms.
NCT01457573 (11) [back to overview]	Change From Baseline in Urinary Growth Factor to Creatinine Ratio (GF/Cr)
NCT01457573 (11) [back to overview]	Change in Post Void Residual (mL) at Baseline Compared to Post Dose Exposure at Mo.1, Mo, 2, and Mo. 3/Wk12
NCT01457573 (11) [back to overview]	Change in PBC-Patient Perception of Bladder Condition at Baseline Compared to Post Dose Exposure at Mo.1, Mo, 2, and Mo. 3/Wk12
NCT01457573 (11) [back to overview]	Change in PPUS-Patient Perception of Urinary Urgency Survey Score at Baseline Compared to Post Dose Exposure at Mo.1, Mo, 2, and Mo. 3/Wk12
NCT01457573 (11) [back to overview]	Change in Urinary Growth Factor to Creatinine Ratio (GF/Cr) From Baseline Compared to Month 1/Week4 and Month 2/Week 8.
NCT01457573 (11) [back to overview]	Change in Maximum Urinary Flow Rate (ml/s) at Baseline Compared to Post Dose Exposure at Mo.1, Mo, 2, and Mo. 3/Wk12
NCT01457573 (11) [back to overview]	Change in IPSS-International Prostate Score Scale at Baseline Compared to Post Dose Survey at Month 1, 2, and Month 3/Week12.
NCT01457573 (11) [back to overview]	Change in ICIQ-MLUTS - International Consultation on Incontinence Modular Questionnaire for Male LUTS Baseline Compared to Post Dose Exposure at Mo.1, Mo, 2, and Mo. 3/Wk12
NCT01457573 (11) [back to overview]	Change in ICIQ LUTS QoL -International Consultation on Incontinence Modular Questionnaire LUTS Quality of Life for Male LUTS Baseline Compared to Post Dose Exposure at Mo.1, Mo, 2, and Mo. 3/Wk12
NCT01457573 (11) [back to overview]	Change in Urinary Nerve Growth Factor (pg/mL) at Baseline Compared to Post Dose Exposure at Mo.1/Wk4 and Mo.2/Wk8
NCT01457573 (11) [back to overview]	Change in Urinary Nerve Growth Factor (pg/mL) at Baseline Compared to Post Dose Exposure at Mo.3/Wk12
NCT01470001 (3) [back to overview]	Change in Patients Perspective of the Impact of Their Disease, Captured Using the Pelvic Floor Distress Inventory (Urinary Questions)
NCT01470001 (3) [back to overview]	the Percent of Patients With at Least 50% Reduction in Post Void Dribbling Episodes
NCT01470001 (3) [back to overview]	The Percent Reduction in Post Void Dribbling Episodes (Events)
NCT01533597 (6) [back to overview]	Change in Mean Number of Micturition Episodes Per 24 Hours
NCT01533597 (6) [back to overview]	Change in Score of IPSS
NCT01533597 (6) [back to overview]	Change of PVR
NCT01533597 (6) [back to overview]	Change of Qmax
NCT01533597 (6) [back to overview]	Numeric Change of Urgency Episodes Per 24 Hours
NCT01533597 (6) [back to overview]	Change in Total Score of OABSS
NCT01559389 (3) [back to overview]	Change in Overall Sexual Satisfaction Among Healthy Male Partners
NCT01559389 (3) [back to overview]	Baseline Sexual Satisfaction Between Matched Female and Male Partners
NCT01559389 (3) [back to overview]	Change in Overall Sexual Satisfaction Among Females
NCT01565694 (16) [back to overview]	Change From Baseline to Last Possible Titration Step in Maximum Cystometric Capacity
NCT01565694 (16) [back to overview]	Change From Baseline in Average Catheterized Volume Per Catheterization
NCT01565694 (16) [back to overview]	Change From Baseline in Average First Morning Catheterized Volume
NCT01565694 (16) [back to overview]	Change From Baseline in Bladder Compliance
NCT01565694 (16) [back to overview]	Change From Baseline in Bladder Volume at 40 cmH2O Detrusor Pressure
NCT01565694 (16) [back to overview]	Change From Baseline in Detrusor Pressure at the End of Bladder Filling
NCT01565694 (16) [back to overview]	Change From Baseline in Maximum Catheterized Volume
NCT01565694 (16) [back to overview]	Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours
NCT01565694 (16) [back to overview]	Change From Baseline in Number of Dry (Incontinence-Free) Days Per 7 Days
NCT01565694 (16) [back to overview]	Change From Baseline in Number of Dry (Incontinence-Free) Nights Per 7 Days
NCT01565694 (16) [back to overview]	Change From Baseline in Number of Overactive Detrusor Contractions (> 15 cmH2O) Until End of Bladder Filling
NCT01565694 (16) [back to overview]	Change From Baseline in Quality of Life [QoL] (PinQ Questionnaire Score)
NCT01565694 (16) [back to overview]	Change From Baseline to Week 24 in Maximum Cystometric Capacity (MCC)
NCT01565694 (16) [back to overview]	Number of Participants With Adverse Events
NCT01565694 (16) [back to overview]	Change From Baseline in Bladder Volume at 30 cmH2O Detrusor Pressure
NCT01565694 (16) [back to overview]	Change From Baseline in Bladder Volume (mL) Until First Detrusor Contraction > 15 cmH2O as a Percentage of Expected Bladder Capacity (EBC)
NCT01565707 (20) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Daytime Micturitions Per 24 Hours
NCT01565707 (20) [back to overview]	Area Under the Plasma Concentration - Time to Curve (AUC) for a Dose Interval (AUCtau) of Solifenacin
NCT01565707 (20) [back to overview]	Change From Baseline in Post Void Residual (PVR) Volume
NCT01565707 (20) [back to overview]	Change From Baseline to End of Treatment (EoT) in Mean Volume Voided (MVV) Per Micturition
NCT01565707 (20) [back to overview]	Change From Baseline to End of Treatment in Daytime Maximum Volume Voided (DMaxVV) Per Micturition
NCT01565707 (20) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Daytime Incontinence Episodes Per 24 Hours
NCT01565707 (20) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT01565707 (20) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Dry (Incontinence-Free) Days Per 7 Days
NCT01565707 (20) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Dry (Incontinence-Free) Nighttimes Per 7 Days
NCT01565707 (20) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Grade 3 or 4 Urgency Episodes Per 24 Hours in Adolescents
NCT01565707 (20) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours
NCT01565707 (20) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Micturitions Per 24 Hours
NCT01565707 (20) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Nighttime Incontinence Episodes Per 24 Hours
NCT01565707 (20) [back to overview]	Change From Baseline to End of Treatment in Mean Number of Nighttime Micturitions Per 24 Hours
NCT01565707 (20) [back to overview]	Maximum Concentration (Cmax) of Solifenacin
NCT01565707 (20) [back to overview]	Plasma Concentration Before Drug Administration (Ctrough) of Solifenacin
NCT01565707 (20) [back to overview]	Time to Attain Maximum Concentration (Tmax) of Solifenacin
NCT01565707 (20) [back to overview]	Apparent Terminal Elimination Half-Life (T1/2) of Solifenacin
NCT01565707 (20) [back to overview]	Apparent Total Body Clearance (CL/F) of Solifenacin
NCT01565707 (20) [back to overview]	Apparent Volume of Distribution (Vz/F) of Solifenacin
NCT01638000 (47) [back to overview]	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 12 and the Final Visit in the Patient's Assessment of Treatment Satisfaction (TS)-Visual Analog Scale (VAS)
NCT01638000 (47) [back to overview]	Change From Baseline to Week 12 and the Final Visit in the Patient's Assessment of Treatment Satisfaction Questionnaire-Likert Scale
NCT01638000 (47) [back to overview]	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Percentage of Participants With Zero Incontinence Episodes at Weeks 4, 8, 12 and Final Visit
NCT01638000 (47) [back to overview]	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Patient Perception of Bladder Condition (PPBC)
NCT01638000 (47) [back to overview]	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Symptom Bother Score as Assessed by the Overactive Bladder Questionnaire (OAB-q)
NCT01638000 (47) [back to overview]	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Total Health-Related Quality of Life (HRQoL) Score as Assessed by the OAB-q
NCT01638000 (47) [back to overview]	Number of Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit
NCT01638000 (47) [back to overview]	Number of Nocturia Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit
NCT01638000 (47) [back to overview]	Number of Pads Used at 4, 8 and 12 Weeks of Treatment and at the Final Visit
NCT01638000 (47) [back to overview]	Number of Urgency Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit
NCT01638000 (47) [back to overview]	Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period
NCT01638000 (47) [back to overview]	Percentage of Participants With 50% Reduction in Incontinence Episodes at Weeks 4, 8, 12 and Final Visit
NCT01638000 (47) [back to overview]	Percentage of Participants With Improvement in HRQoL Scales as Assessed by the OAB-q: ≥10 Points Improvement in OAB-q at Week 12 and Final Visit
NCT01638000 (47) [back to overview]	Percentage of Participants With Improvement in PPBC: ≥1 Point Improvement at Week 12 and Final Visit
NCT01638000 (47) [back to overview]	Percentage of Participants With Improvement in Symptom Bother Score as Assessed by the OAB-q: ≥ 10 Points Improvement in OAB-q at Week 12 and Final Visit
NCT01638000 (47) [back to overview]	Percentage of Participants With Improvement in Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Final Visit
NCT01638000 (47) [back to overview]	Percentage of Participants With Improvement of Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Week 12
NCT01638000 (47) [back to overview]	Percentage of Participants With Major Improvement in PPBC: ≥2 Point Improvement at Week 12 and Final Visit
NCT01638000 (47) [back to overview]	Percentage of Participants With Normalization of Micturitions at Weeks 4, 8, 12 and Final Visit
NCT01638000 (47) [back to overview]	Change From Baseline to Final Visit in the Mean Number of Micturitions Per 24 Hours
NCT01638000 (47) [back to overview]	Change From Baseline in Mean Number of Nocturia Episodes Per 24 Hours After 4, 8 and 12 Weeks of Treatment
NCT01638000 (47) [back to overview]	Change From Baseline in Mean Number of Pads Used Per 24 Hours After 4, 8 and 12 Weeks of Treatment
NCT01638000 (47) [back to overview]	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Level of Urgency
NCT01638000 (47) [back to overview]	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours
NCT01638000 (47) [back to overview]	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Incontinence Episodes Per 24 Hours
NCT01638000 (47) [back to overview]	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Micturitions Per 24 Hours
NCT01638000 (47) [back to overview]	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT01638000 (47) [back to overview]	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01638000 (47) [back to overview]	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire
NCT01642277 (3) [back to overview]	Bacterial Genomic Sequencing
NCT01642277 (3) [back to overview]	Assessment of Pelvic Floor Disease Inventory (PFDI) Questionnaire
NCT01642277 (3) [back to overview]	Assessment of Overactive Bladder Questionnaire (OABQ)
NCT01655069 (6) [back to overview]	Change From Baseline to Final Visit in Postvoid Residual (PVR) Volume
NCT01655069 (6) [back to overview]	Change From Baseline in Mean Number of Grade 3 or 4 Urgency Episodes Per 24 Hours in Adolescents
NCT01655069 (6) [back to overview]	Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours
NCT01655069 (6) [back to overview]	Change From Baseline in Mean Number of Micturitions Per 24 Hours
NCT01655069 (6) [back to overview]	Change From Baseline in Number of Dry (Incontinence-Free) Days Per 7 Days
NCT01655069 (6) [back to overview]	Number of Participants With and Severity of Treatment-Emergent Adverse Events (TEAEs)
NCT01745094 (15) [back to overview]	Change From Baseline in Overactive Bladder Questionnaire Short Form (OAB-q SF) Severity Score
NCT01745094 (15) [back to overview]	Change From Baseline in Postvoid Residual (PVR) Volume
NCT01745094 (15) [back to overview]	Number for Participants Who Achieved Normalization of the Number of Incontinence Episodes Per 24 Hours
NCT01745094 (15) [back to overview]	Number for Participants Who Achieved Normalization of the Number of Micturitions Per 24 Hours
NCT01745094 (15) [back to overview]	Number for Participants Who Achieved Normalization of the Number of Urgency Episodes Per 24 Hours
NCT01745094 (15) [back to overview]	Change From Baseline in OAB-q SF Total HRQL Score
NCT01745094 (15) [back to overview]	Change From Baseline in OABSS Total Score
NCT01745094 (15) [back to overview]	Change From Baseline in the Number of Incontinence Episodes Per 24 Hours
NCT01745094 (15) [back to overview]	Change From Baseline in the Number of Micturitions Per 24 Hours
NCT01745094 (15) [back to overview]	Change From Baseline in the Number of Nocturia Episodes Per Night
NCT01745094 (15) [back to overview]	Change From Baseline in the Number of Urge Incontinence Episodes Per 24 Hours
NCT01745094 (15) [back to overview]	Change From Baseline in the Number of Urgency Episodes Per 24 Hours
NCT01745094 (15) [back to overview]	Change From Baseline in the Volume Voided Per Micturition
NCT01745094 (15) [back to overview]	Number of Participants Who Achieved Normalization for OABSS Total Score
NCT01745094 (15) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT01767519 (7) [back to overview]	Change From Study Baseline in Number of Episodes of Urinary Incontinence in Treatment Cycle 1
NCT01767519 (7) [back to overview]	Change From Study Baseline in the Role Limitations Domain on the King's Health Questionnaire in Treatment Cycle 1
NCT01767519 (7) [back to overview]	Percentage of Patients With 100% Reduction in Incontinence Episodes in Treatment Cycle 1
NCT01767519 (7) [back to overview]	Percentage of Patients With a Positive Response on the Single-Item Treatment Benefit Scale During Treatment Cycle 1
NCT01767519 (7) [back to overview]	Change From Study Baseline in the Number of Micturition Episodes in Treatment Cycle 1
NCT01767519 (7) [back to overview]	Change From Study Baseline in the Number of Nocturia Episodes in Treatment Cycle 1
NCT01767519 (7) [back to overview]	Change From Study Baseline in the Social Limitations Domain on the King's Health Questionnaire in Treatment Cycle 1
NCT01777217 (1) [back to overview]	Change From Baseline to End of Study Measured by the American Urology Association Symptom Score Questionnaire (AUASS).
NCT01908829 (36) [back to overview]	Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Self-care
NCT01908829 (36) [back to overview]	Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Pain/Discomfort
NCT01908829 (36) [back to overview]	Change From Baseline in OAB-q HRQL Subscale Score: Social Interaction
NCT01908829 (36) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT01908829 (36) [back to overview]	Number of Participants in Each Category of Patient and Clinician Global Impression of Change Scales (PGIC and CGIC)
NCT01908829 (36) [back to overview]	Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Anxiety/Depression
NCT01908829 (36) [back to overview]	Number of Pads Used During the 3-Day Diary
NCT01908829 (36) [back to overview]	Number of Nocturia Episodes Reported Over 3-Day Diary
NCT01908829 (36) [back to overview]	Number of Incontinence Episodes Reported During the 3-Day Diary
NCT01908829 (36) [back to overview]	Change From Baseline to Weeks 4, 8 & 12 in Mean Number of Incontinence Episodes Per 24 Hours
NCT01908829 (36) [back to overview]	Change From Baseline in Overactive Bladder Symptom (OAB-q) Symptom Bother Score
NCT01908829 (36) [back to overview]	Change From Baseline in Treatment Satisfaction - Visual Analogue Scale (TS-VAS) Score
NCT01908829 (36) [back to overview]	Change From Baseline in Post Void Residual (PVR) Volume
NCT01908829 (36) [back to overview]	Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours
NCT01908829 (36) [back to overview]	Change From Baseline in OAB-q HRQL Subscale Score: Sleep
NCT01908829 (36) [back to overview]	Change From Baseline in OAB-q HRQL Subscale Score: Coping
NCT01908829 (36) [back to overview]	Change From Baseline in OAB-q HRQL Subscale Score: Concern
NCT01908829 (36) [back to overview]	Change From Baseline in OAB-q Health-Related Quality of Life (HRQL) Total Score
NCT01908829 (36) [back to overview]	Change From Baseline in Mean Volume Voided (MVV) Per Micturition
NCT01908829 (36) [back to overview]	Change From Baseline in Mean Number of Urgency Incontinence (UI) Episodes Per 24 Hours
NCT01908829 (36) [back to overview]	Change From Baseline in Mean Number of Urgency Episodes (Grade 3 and/or 4) Per 24 Hours
NCT01908829 (36) [back to overview]	Change From Baseline in Mean Number of Pads Per 24 Hours
NCT01908829 (36) [back to overview]	Change From Baseline in Mean Number of Nocturia Episodes
NCT01908829 (36) [back to overview]	Change From Baseline in Mean Number of Micturitions Per 24 Hours
NCT01908829 (36) [back to overview]	Change From Baseline to EoT in Corrected Micturition Frequency (CMF)
NCT01908829 (36) [back to overview]	Change From Baseline in Patient Perception Bladder Control (PPBC) Score
NCT01908829 (36) [back to overview]	Percentage of Participants With Zero Incontinence Episodes Postbaseline
NCT01908829 (36) [back to overview]	Percentage of Participants With at Least a 10-Point Improvement From Baseline in HRQL Total Score
NCT01908829 (36) [back to overview]	Percentage of Participants With Major (at Least 2-Point) Improvement From Baseline in PPBC
NCT01908829 (36) [back to overview]	Percentage of Participants With at Least a 50% Decrease From Baseline in Mean Number of Incontinence Episodes Per 24 Hours
NCT01908829 (36) [back to overview]	Percentage of Participants With at Least a 10-Point Improvement From Baseline in OAB-q Symptom Bother Score
NCT01908829 (36) [back to overview]	Percentage of Participants With at Least a 1-Point Improvement From Baseline in PPBC
NCT01908829 (36) [back to overview]	Percentage of Participants With a Mean of at Least 8 Micturitions Per 24 Hours at Baseline and Less Than 8 Micturitions Per 24 Hours Postbaseline
NCT01908829 (36) [back to overview]	Number of UI Episodes Reported During the 3-Day Diary
NCT01908829 (36) [back to overview]	Number of Participants With Change From Baseline to EoT in Euroqol European Quality of Life-5 Dimensions (EQ-5D) Subscale Score: Mobility
NCT01908829 (36) [back to overview]	Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Usual Activities
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Pads Used Per 24 Hours
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Incontinence Episodes
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 12 and EoT in Mean 24-hours, Mean Daytime and Mean Nighttime Systolic Blood Pressure (SBP)
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Pads Used
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Urgency Incontinence Episodes
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q Health-Related Quality of Life Questionnaire (HRQL) Total Score
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Concern
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Coping
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Sleep
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Social
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Patient Perception of Bladder Condition Questionnaire (PPBC)
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Postvoid Residual (PVR) Volume
NCT01972841 (70) [back to overview]	Maximum 1-hour Change From Time-matched Baseline in DBP at Weeks 4, 12 and EoT
NCT01972841 (70) [back to overview]	Maximum 1-hour Change From Time-matched Baseline in PR at Weeks 4, 12 and EoT
NCT01972841 (70) [back to overview]	Maximum 1-hour Change From Time-matched Baseline in SBP at Weeks 4, 12 and EoT
NCT01972841 (70) [back to overview]	Number of Days With < 8 Micturitions at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Number of Incontinence Episodes at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 12 and EoT in Mean 24-h, Mean Daytime and Mean Nighttime Pulse Rate (PR)
NCT01972841 (70) [back to overview]	Number of Incontinence-Free Days With < 8 Micturitions at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Number of Nocturia Episodes at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Number of Pads Used at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT01972841 (70) [back to overview]	Number of Urgency Incontinence Episodes at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Patient's Global Impression of Change (PGIC) Scale: Impression in Bladder Symptoms at Week 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants for Micturition Frequency Normalization at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q HRQL Total Score) at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q Symptom Bother Scale) at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, at Least 10 Points Improvement on OAB-q HRQL Total Score and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, at Least 10 Points Improvement on OAB-q Symptom Bother Scale and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants With ≥ 1 Point Improvement From Baseline in PPBC at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants With ≥ 10 Points Improvement From Baseline in HRQL Total Score at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants With ≥ 10 Points Improvement From Baseline in the OAB-q Symptom Bother Score at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 12 and EoT in Mean 24-h, Mean Daytime and Mean Nighttime Diastolic Blood Pressure (DBP)
NCT01972841 (70) [back to overview]	Percentage of Participants With Major (≥ 2 Points) Improvement From Baseline in PPBC at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 3 Diary Days at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 7 Diary Days at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	PGIC Scale: Impression in General Health at Week 12 and EoT
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 12 and EoT in DBP Peak/Trough Difference
NCT01972841 (70) [back to overview]	Change From Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Overall Work Impairment
NCT01972841 (70) [back to overview]	Change From Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Impairment While Working
NCT01972841 (70) [back to overview]	Change From Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Activity Impairment
NCT01972841 (70) [back to overview]	Change From Baseline to Week 12 and EoT in Work Productivity and Activity Impairment: Specific Health Problem Questionnaire (WPAI:SHP) Score: Percent Work Time Missed
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in European Quality of Life in 5 Dimensions (EQ-5D) Questionnaire Subscale Score: Mobility
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Usual Activities
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Self-Care
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Pain/Discomfort
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Anxiety/Depression
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in Treatment Satisfaction-Visual Analogue Scale (TS-VAS)
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score
NCT01972841 (70) [back to overview]	Percentage of Participants With 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours at Weeks 4, 8, 12 and EoT
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 12 and EoT in Mean DBP in the Tmax Window
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in Mean Number of Micturitions Per 24 Hours
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in Corrected Micturition Frequency
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Nocturia Episodes
NCT01972841 (70) [back to overview]	Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours
NCT01972841 (70) [back to overview]	Change From Baseline to EoT in Mean Volume Voided Per Micturition
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 12 and EoT in Mean PR in the Tmax Window
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 12 and EoT in Mean SBP in the Time to Maximum Concentration (Tmax) Window
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 12 and EoT in PR Peak/Trough Difference
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 12 and EoT in SBP Peak/Trough Difference
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8 and 12 in Mean Number of Incontinence Episodes Per 24 Hours
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8 and 12 in Mean Number of Micturitions Per 24 Hours
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8 and 12 in Mean Volume Voided Per Micturition
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8 and 12 in the OAB-q Symptom Bother Score
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8 and 12 in TS-VAS
NCT01972841 (70) [back to overview]	Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Nocturia Episodes Per 24 Hours
NCT01972841 (70) [back to overview]	Number of Incontinence-Free Days at Weeks 4, 8, 12 and EoT
NCT01981954 (42) [back to overview]	Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 6
NCT01981954 (42) [back to overview]	Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 9
NCT01981954 (42) [back to overview]	Percentage of Days With of Incontinence for Each Hour of 24 Hour Day During Week 3
NCT01981954 (42) [back to overview]	Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume at 20 cmH20 Detrusor Pressure
NCT01981954 (42) [back to overview]	Change From Baseline to Week 24 in Maximum Cystometric Capacity (MCC)
NCT01981954 (42) [back to overview]	Change From Baseline to Week 24 and 52 in Infant and Toddler Quality of Life Short Form-47 Questionnaire (ITQoL SF-47) - Overall Health Score
NCT01981954 (42) [back to overview]	Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Behaviour Score
NCT01981954 (42) [back to overview]	Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Change in Health Score
NCT01981954 (42) [back to overview]	Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Family Cohesion Impact Score
NCT01981954 (42) [back to overview]	Change From Baseline to Week 24 and 52 in ITQoL SF-47 - General Health Score
NCT01981954 (42) [back to overview]	Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Growth and Development Score
NCT01981954 (42) [back to overview]	Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Pain Score
NCT01981954 (42) [back to overview]	Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Parent-Emotional Impact Score
NCT01981954 (42) [back to overview]	Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Parent-Time Impact Score
NCT01981954 (42) [back to overview]	Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Physical Abilities Score
NCT01981954 (42) [back to overview]	Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Temperament and Moods Score
NCT01981954 (42) [back to overview]	Change From Baseline to Weeks 3, 6, 9, 12 and 52 in MCC
NCT01981954 (42) [back to overview]	Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Compliance
NCT01981954 (42) [back to overview]	Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume at 10 cmH20 Detrusor Pressure
NCT01981954 (42) [back to overview]	Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume at 30 cmH20 Detrusor Pressure
NCT01981954 (42) [back to overview]	Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume Until First Detrusor Contraction (> 15 cmH2O)
NCT01981954 (42) [back to overview]	Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Catheterized Volume 5 Minutes After End of Bladder-Filling
NCT01981954 (42) [back to overview]	Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Detrusor Pressure 5 Minutes After End of Bladder-Filling
NCT01981954 (42) [back to overview]	Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Detrusor Pressure at End of Bladder-Filling
NCT01981954 (42) [back to overview]	Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Number of Overactive Detrusor Contractions (> 15 cmH2O) Until Leakage or End of Bladder-Filling
NCT01981954 (42) [back to overview]	Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Average Catheterized Volume Per Catheterization
NCT01981954 (42) [back to overview]	Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Average First Morning Catheterized Volume
NCT01981954 (42) [back to overview]	Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Maximum Catheterized Volume (MCV)
NCT01981954 (42) [back to overview]	Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Mean Number of Periods Between the Clean Intermittent Catheterizations (CICs) With Incontinence Per 24 Hours
NCT01981954 (42) [back to overview]	Percentage of Days With Catheterizations for Each Hour of 24 Hour Day at Baseline
NCT01981954 (42) [back to overview]	Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 12
NCT01981954 (42) [back to overview]	Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 24
NCT01981954 (42) [back to overview]	Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 3
NCT01981954 (42) [back to overview]	Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 36
NCT01981954 (42) [back to overview]	Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 52
NCT01981954 (42) [back to overview]	Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 6
NCT01981954 (42) [back to overview]	Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 9
NCT01981954 (42) [back to overview]	Percentage of Days With Incontinence for Each Hour of 24 Hour Day at Baseline
NCT01981954 (42) [back to overview]	Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 12
NCT01981954 (42) [back to overview]	Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 24
NCT01981954 (42) [back to overview]	Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 36
NCT01981954 (42) [back to overview]	Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 52
NCT02045862 (53) [back to overview]	Change From Baseline to Months 3, 6 and 12 in Mean Volume Voided Per Micturition
NCT02045862 (53) [back to overview]	Change From Baseline to Months 6, 12 and EoT in Work Productivity and Activity Impairment: Specific Health Problem Questionnaire (WPAI:SHP) Score: Percent Work Time Missed
NCT02045862 (53) [back to overview]	Number of Incontinence-Free Days During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Change From Baseline to Months 6, 12 and EoT in WPAI:SHP Score: Percent Impairment While Working
NCT02045862 (53) [back to overview]	Change From Baseline to Months 6, 12 in WPAI:SHP Score: Percent Activity Impairment
NCT02045862 (53) [back to overview]	Change From Baseline to Months 6, 12 in WPAI:SHP Score: Percent Overall Work Impairment
NCT02045862 (53) [back to overview]	Number of Days With < 8 Micturitions Per Day During the 7-Day Micturition Diary Period Prior to Each Visit (at Months 1, 3, 6, 9, 12 and EoT)
NCT02045862 (53) [back to overview]	Number of Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQoL Subscale Score: Coping
NCT02045862 (53) [back to overview]	Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 7 Diary Days at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 3 Diary Days at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants With Micturition Frequency Normalization at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants With Major (≥ 2 Points) Improvement From Baseline in PPBC at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants With 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants With ≥ 10 Points Improvement From Baseline in the OAB-q Symptom Bother Score at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants With ≥ 10 Points Improvement From Baseline in HRQoL Total Score at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants With ≥ 1 Point Improvement From Baseline in PPBC at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants Who Were Triple Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, ≥ 10 Points Improvement on OAB-q Symptom Bother Scale and ≥1 Point Improvement on PPBC) at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants Who Were Double Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q Symptom Bother Scale) at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants Who Were Double Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q HRQL Total Score) at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants Who Were Double Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 1 Point Improvement on PPBC) at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants in Each Category of PGIC Scale: Impression in General Health at Month 12 and EoT
NCT02045862 (53) [back to overview]	Percentage of Participants in Each Category of Patient's Global Impression of Change (PGIC) Scale: Impression in Bladder Symptoms at Month 12 and EoT
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQoL Subscale Score: Concern
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQL Subscale Score: Social
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Health-Related Quality of Life Questionnaire (HRQoL): Total Score
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9 and 12 in the Patient's Assessment of TS-VAS
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9 and 12 in the OAB-q Symptom Bother Score
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9 and 12 in Mean Number of Micturitions Per 24 Hours
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9 and 12 in Mean Number of Incontinence Episodes Per 24 Hours
NCT02045862 (53) [back to overview]	Change From Baseline to EoT in the Patient's Assessment of Treatment Satisfaction-Visual Analogue Scale (TS-VAS)
NCT02045862 (53) [back to overview]	Change From Baseline to EoT in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score
NCT02045862 (53) [back to overview]	Change From Baseline to EoT in Mean Volume Voided Per Micturition
NCT02045862 (53) [back to overview]	Change From Baseline to EoT in Mean Number of Micturitions Per 24 Hours
NCT02045862 (53) [back to overview]	Change From Baseline to EoT in Corrected Micturition Frequency
NCT02045862 (53) [back to overview]	Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours
NCT02045862 (53) [back to overview]	Participants Who Were Triple Responders (≥ 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, ≥ 10 Points Improvement on OAB-q HRQL Total Score and ≥ 1 Point Improvement on PPBC) at Months 1, 3, 6, 9, 12 and EoT
NCT02045862 (53) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT02045862 (53) [back to overview]	Number of Pads Used During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Number of Nocturia Episodes Reported During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Number of Incontinence-Free Days With < 8 Micturitions Per Day During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Number of Urgency Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in HRQoL Subscale Score: Sleep
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Nocturia Episodes Per 24 Hours
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Pads Used Per 24 Hours
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Mean Number of Urgency Incontinence Episodes Per 24 Hours
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Nocturia Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Pads Used During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Number of Urgency Incontinence Episodes During the 7-Day Micturition Diary Period Prior to Each Visit
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Patient Perception of Bladder Condition (PPBC)
NCT02045862 (53) [back to overview]	Change From Baseline to Months 1, 3, 6, 9, 12 and EoT in Postvoid Residual (PVR) Volume
NCT02047032 (12) [back to overview]	Percentage of Change From Baseline in 72-hour Incontinence Episode Frequency (IEF) Over Weeks 1-12
NCT02047032 (12) [back to overview]	Change of Episodes From Baseline in Mean 72-h Incontinence Episodes
NCT02047032 (12) [back to overview]	Patient's Treatment Satisfaction Degree
NCT02047032 (12) [back to overview]	Patient Global Impression Improvement
NCT02047032 (12) [back to overview]	Weekly Median Number of Urine Pads Used During Weeks 1-12, 13-24, and 25-36
NCT02047032 (12) [back to overview]	The Number of Participants Using Urine Pads
NCT02047032 (12) [back to overview]	the Amount of Urine Leakage (Grams) Measured by the 1-hour Pad Test at Weeks 4 and 12
NCT02047032 (12) [back to overview]	Percentage of Participants With ≥50% Decrease in Average 72-h Incontinence Episode Frequency
NCT02047032 (12) [back to overview]	Percentage of Change From Baseline in Mean 72-hour IEF During Weeks 13-24 and Weeks 25-36
NCT02047032 (12) [back to overview]	Electroacupuncture Acceptance Assessment
NCT02047032 (12) [back to overview]	Change of Episodes From Baseline in Average 72-hour Urgencies/Urination/Nocturia Episodes
NCT02047032 (12) [back to overview]	Change From Baseline in the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Score
NCT02294396 (16) [back to overview]	Number for Participants Who Achieved Normalization of the Mean Number of Incontinence Episodes Per 24 Hours
NCT02294396 (16) [back to overview]	Number for Participants Who Achieved Normalization of the Mean Number of Micturitions Per 24 Hours
NCT02294396 (16) [back to overview]	Number for Participants Who Achieved Normalization of the Mean Number of Urgency Episodes Per 24 Hours
NCT02294396 (16) [back to overview]	Number of Participants Who Achieved Normalization for OABSS Total Score
NCT02294396 (16) [back to overview]	Number of Participants Who Achieved Normalization of the Mean Number of Nocturia Episodes Per 24 Hours
NCT02294396 (16) [back to overview]	Change From Baseline in OAB-q SF Total HRQL Score
NCT02294396 (16) [back to overview]	Change From Baseline in Overactive Bladder Questionnaire Short Form (OAB-q SF) Symptom Severity Score
NCT02294396 (16) [back to overview]	Change From Baseline in Overactive Bladder Symptom Score (OABSS) Total Score
NCT02294396 (16) [back to overview]	Change From Baseline in Postvoid Residual (PVR) Volume
NCT02294396 (16) [back to overview]	Change From Baseline in the Mean Number of Incontinence Episodes Per 24 Hours
NCT02294396 (16) [back to overview]	Change From Baseline in the Mean Number of Micturitions Per 24 Hours
NCT02294396 (16) [back to overview]	Change From Baseline in the Mean Number of Nocturia Episodes Per Night
NCT02294396 (16) [back to overview]	Change From Baseline in the Mean Number of Urge Incontinence Episodes Per 24 Hours
NCT02294396 (16) [back to overview]	Change From Baseline in the Mean Number of Urgency Episodes Per 24 Hours
NCT02294396 (16) [back to overview]	Change From Baseline in the Mean Volume Voided Per Micturition
NCT02294396 (16) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT02549196 (2) [back to overview]	Number of Participants Who Reached the Maximum Allowed Dose (MAD) in Their Respective Cohort
NCT02549196 (2) [back to overview]	Number of Participants With TEAEs Leading to Study Drug Discontinuation
NCT04090190 (2) [back to overview]	The Effectiveness of Anticholinergic Treatment in Relation to the Urinary Microbiome. Culture to Standard Culture Media Will Pickup Aerobic Bacteria and Yeasts After DNA Extraction and End Point PCR for 16S rDNA Genes.
NCT04090190 (2) [back to overview]	Inflammatory Markers in Urine Will be Measured Using Immunoenzyme Assays to Measure the Interaction of Anticholinergic Treatment and the Inflammatory Milieu.

Change From Baseline in Urgency Episodes as Reported in Subject 3-day Diary

"Subjects were instructed to complete the diary in the 3 day period immediately preceding the visit. Subjects recorded each urgency episode or instance of strong desire to pass urine.~The mean was calculated for each time point as the average of the day 1-3 measurements from the associated 3 day diary. Change from Baseline was calculated as Week 8- Baseline." (NCT00431041)
Timeframe: Baseline and 8 weeks

Intervention	urgency episodes per day (Mean)
	Change in urgency episodes at 8 weeks (N=52; 40)	Urgency episodes at Baseline (N= 68; 64)	Urgency episodes at 8 weeks (N=52; 40)
Oxybutynin IR	-3.70	6.6	2.1
Solifenacin	-2.65	6.3	3.8

Intervention	Micturitions per day (Mean)
	Change in micturition frequency at 8 wks(N=52; 40)	Micturition frequency at Baseline (N=68; 64)	Micturition frequency at 8 weeks (N=52; 40)
Oxybutynin IR	-3.1	12.5	9.0
Solifenacin	-2.3	12.4	9.9

Intervention	units on a scale (Least Squares Mean)
	Week 2 (N=62, 67, 58)	Week 4 (N=60, 66, 58)	Week 8 (N=58, 67, 58)	Week 12 (N=58, 63, 57)	End of Treatment (N=62, 67, 59)
6 mg Solifenacin + 0.4 mg Tamsulosin	-1.6	-2.6	-2.8	-3.3	-3.4
9 mg Solifenacin + 0.4 mg Tamsulosin	-2.1	-2.5	-3.1	-3.1	-3.0
Placebo	-1.5	-2.1	-2.7	-2.8	-2.7

Intervention	units on a scale (Least Squares Mean)
	Week 2 (N=61, 67, 58)	Week 4 (N=60, 65, 57)	Week 8 (N=58, 67, 57)	Week 12 (N=58, 64, 57)	End of Treatment (N=62, 67, 59)
6 mg Solifenacin + 0.4 mg Tamsulosin	-2.9	-3.8	-4.3	-4.7	-4.6
9 mg Solifenacin + 0.4 mg Tamsulosin	-2.6	-3.6	-3.8	-4.1	-3.9
Placebo	-2.2	-3.2	-4.1	-4.0	-3.9

Intervention	incontinence episodes (Least Squares Mean)
	Week 2 (N=13, 10, 13)	Week 4 (N=13, 10, 13)	Week 8 (N=12, 10, 12)	Week 12 (N=12, 9, 12)	End of Treatment (N=13, 10, 13)
6 mg Solifenacin + 0.4 mg Tamsulosin	-1.45	-1.45	-1.55	-1.48	-1.66
9 mg Solifenacin + 0.4 mg Tamsulosin	-1.01	-0.81	-0.78	-0.85	-1.02
Placebo	-0.81	-1.00	-1.86	-1.99	-1.54

Intervention	micturitions (Least Squares Mean)
	Week 2 (N=60, 67, 59)	Week 4 (N=60, 65, 58)	Week 8 (N=58, 67, 58)	Week 12 (N=58, 65, 58)	End of Treatment (N=60, 67, 59)
6 mg Solifenacin + 0.4 mg Tamsulosin	-1.25	-1.32	-1.31	-1.91	-1.91
9 mg Solifenacin + 0.4 mg Tamsulosin	-1.19	-1.72	-2.00	-1.89	-1.87
Placebo	-0.44	-1.03	-1.33	-1.07	-0.95

Intervention	units on a scale (Least Squares Mean)
	Week 2 (N=61, 66, 58)	Week 4 (N=60, 66, 58)	Week 8 (N=58, 67, 58)	Week 12 (N=58, 64, 57)	End of Treatment (N=62, 67, 59)
6 mg Solifenacin + 0.4 mg Tamsulosin	-0.3	-0.5	-0.8	-1.0	-0.9
9 mg Solifenacin + 0.4 mg Tamsulosin	-0.5	-0.9	-1.1	-1.1	-1.1
Placebo	-0.5	-0.7	-1.0	-1.1	-1.1

Intervention	mL (Least Squares Mean)
	Week 2 (N=61, 67, 58)	Week 4 (N=60, 67, 59)	Week 8 (N=58, 66, 58)	Week 12 (N=57, 63, 57)	End of Treatment (N=62, 67, 59)
6 mg Solifenacin + 0.4 mg Tamsulosin	16.78	14.92	9.64	26.81	25.63
9 mg Solifenacin + 0.4 mg Tamsulosin	8.97	9.65	6.64	18.72	19.07
Placebo	-10.21	-7.86	-12.44	1.16	0.14

Intervention	participants (Number)
	Any adverse event	Mild adverse event	Moderate adverse event	Severe adverse event	Serious adverse event	AE leading to study drug discontinuation	Drug-related adverse events	Deaths
6 mg Solifenacin + 0.4 mg Tamsulosin	38	21	13	4	2	3	24	0
9 mg Solifenacin + 0.4 mg Tamsulosin	37	20	12	5	2	6	26	0
Placebo	29	21	6	2	1	3	15	0

Intervention	units on a scale (Least Squares Mean)
	Week 4 (N=52, 57, 48)	Week 8 (N=51, 55, 47)	Week 12 (N=51, 51, 47)	End of Treatment (N=58, 60, 53)
6 mg Solifenacin + 0.4 mg Tamsulosin	-11.0	-19.4	-23.9	-21.1
9 mg Solifenacin + 0.4 mg Tamsulosin	-17.0	-20.7	-23.9	-22.4
Placebo	-14.6	-20.7	-22.6	-21.7

Intervention	units on a scale (Least Squares Mean)
	Week 4 (N=57, 66, 56)	Week 8 (N=56, 65, 55)	Week 12 (N=56, 63, 55)	End of Treatment (N=60, 66, 57)
6 mg Solifenacin + 0.4 mg Tamsulosin	-1.2	-1.7	-2.0	-1.9
9 mg Solifenacin + 0.4 mg Tamsulosin	-1.3	-1.8	-2.2	-2.1
Placebo	-1.2	-1.7	-2.1	-2.0

Intervention	Percent voiding efficiency (Least Squares Mean)
Placebo	-0.67
6 mg Solifenacin + 0.4 mg Tamsulosin	-1.38
9 mg Solifenacin + 0.4 mg Tamsulosin	-3.79

Intervention	mL/sec (Least Squares Mean)
Placebo	0.17
6 mg Solifenacin + 0.4 mg Tamsulosin	1.85
9 mg Solifenacin + 0.4 mg Tamsulosin	2.35

Intervention	cmH2O (Least Squares Mean)
Placebo	-1.69
6 mg Solifenacin + 0.4 mg Tamsulosin	-7.84
9 mg Solifenacin + 0.4 mg Tamsulosin	-6.69

Intervention	units on a scale (Least Squares Mean)
Placebo	-1.63
6 mg Solifenacin + 0.4 mg Tamsulosin	1.84
9 mg Solifenacin + 0.4 mg Tamsulosin	3.86

Intervention	units on a scale (Least Squares Mean)
	Week 4 (N=58, 66, 52)	Week 8 (N=55, 63, 53)	Week 12 (N=55, 61, 53)	End of Treatment (N=60, 66, 57)
6 mg Solifenacin + 0.4 mg Tamsulosin	-4.5	-5.6	-6.5	-6.0
9 mg Solifenacin + 0.4 mg Tamsulosin	-4.6	-5.8	-5.9	-5.8
Placebo	-3.9	-5.5	-5.5	-5.2

Intervention	units on a scale (Least Squares Mean)
	Week 4 (N=33, 36, 36)	Week 8 (N=33, 32, 31)	Week 12 (N=35, 33, 28)	End of Treatment (N=39, 39, 38)
6 mg Solifenacin + 0.4 mg Tamsulosin	-2.4	-4.3	-6.5	-5.3
9 mg Solifenacin + 0.4 mg Tamsulosin	-5.1	-6.7	-8.4	-7.3
Placebo	-2.7	-3.6	-4.8	-4.7

Intervention	OAB-q Score (Mean)
	Baseline ( N= 374 ; 377)	Week 4 (N=371; 370)	Change at Week 4 (N=371; 370)	Week 8 (N=342; 356)	Change at Week 8 (N=342; 356)	Week 12 (N=318; 339)	Change at Week 12 (N=318; 339)
Placebo	57.9	41.6	-16.4	37.0	-21.0	36.0	-21.7
Solifenacin Succinate	58.2	35.5	-22.6	29.8	-28.9	27.6	-30.9

Intervention	OAB-q HRQL Sub Domain Score (Mean)
	Coping- Baseline (N= 374 ; 377)	Coping- Change at Week 4 (N=371; 370)	Coping- Change at Week 8 (N=342; 356)	Coping- Change at Week 12 (N=318; 339)	Concern- Baseline (N= 374 ; 377)	Concern- Change at Week 4 (N=371; 370)	Concern- Change at Week 8 (N=342; 356)	Concern- Change at Week 12 (N=318; 339)	Sleep- Baseline (N= 374 ; 377)	Sleep- Change at Week 4 (N=371; 370)	Sleep- Change at Week 8 (N=342; 356)	Sleep- Change at Week 12 (N=318; 339)	Social- Baseline (N= 374 ; 377)	Social- Change at Week 4 (N=371; 370)	Social- Change at Week 8 (N=340; 356)	Social- Change at Week 12 (N=318; 339)
Placebo	53.7	14.9	18.9	19.9	52.0	15.8	19.8	20.9	51.3	13.9	18.7	19.0	78.9	7.8	9.4	10.0
Solifenacin Succinate	52.2	22.2	27.0	28.8	51.9	22.4	28.4	29.9	47.3	19.3	26.2	27.5	78.7	10.3	13.1	13.7

Intervention	ICIQ-MLUTSsex (Mean)
	Symptom- Baseline (N=59; 71)	Symptom- EOT (N=55; 68)	Symptom- Change at EOT (N=54; 68)	Bother- Baseline (N=59; 71)	Bother- EOT (N=51; 67)	Bother- Change at EOT (N=50; 67)
Placebo	3.6	3.2	-0.1	12.1	10.3	-1.6
Solifenacin Succinate	3.5	3.7	0.1	11.8	11.4	-0.6

Intervention	OAB-q Score (Mean)
	Baseline	End of Treatment	Change at End of Treatment
Placebo	57.9	37.5	-20.4
Solifenacin Succinate	58.2	28.3	-29.9

solifenacin succinate

Description

Cross-References

Synonyms (80)

Research Excerpts

Overview

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (3)

Inhibition Measurements

Biological Processes (34)

Molecular Functions (7)

Ceullar Components (18)

Bioassays (19)

Research

Studies (484)

Market Indicators

Research Demand Index: 82.26

Study Types

Clinical Trials (136)

Trial Overview

Trial Outcomes

Change From Baseline in Urgency Episodes as Reported in Subject 3-day Diary

The Number of Subjects Reporting Incidence of Dry Mouth as an Adverse Event

Change From Baseline in Micturition Frequency as Reported in Subject 3-day Diary

The Severity of Dry Mouth Reported as an Adverse Event

Change From Baseline in IPSS Storage Score

Change From Baseline in IPSS Voiding Score

Change From Baseline in Number of Incontinence Episodes Per 24 Hours

Change From Baseline in Number of Micturitions Per 24 Hours

Change From Baseline in Number of Urgency Episodes Per 24 Hours

Change From Baseline in Patient Perception of Bladder Condition (PPBC)

Change From Baseline in Post Void Residual Volume (PVR)

Change From Baseline in Volume Voided Per Micturition

Safety Assessed by Adverse Events (AEs), Electrocardiogram (ECG), Vital Signs, Physical Exam and Laboratory Tests

Change From Baseline in ICIQ-MLUTS Total Symptom Bother Score

Change From Baseline in ICIQ-LUTSqol Overall Symptom Interference of Life Score

Change From Baseline to End of Treatment in Percent Bladder Voiding Efficiency (BVE)

Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax)

Change From Baseline to End of Treatment in Detrusor Pressure at Maximum Flow Rate (PdetQmax)

Change From Baseline to End of Treatment in Bladder Contractility Index (BCI)

Change From Baseline in International Prostate Symptoms Score (IPSS)

Change From Baseline in International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptom (ICIQ MLUTS) Total Symptom Score

Change From Baseline in International Consultation on Incontinence Questionnaire - Lower Urinary Tract Symptom Quality of Life (ICIQ-LUTSqol) Symptom Score

Change From Baseline to Each Visit in Symptom Bother Utilizing the OAB-q Score

Change From Baseline to Each Visit in the OAB-q HRQL Sub-domain Scores of Coping, Concern, Sleep and Social

Change From Baseline in International Consultation on Incontinence Modular Questionnaire Male Sexual Matters Associated With Lower Urinary Tract Symptoms (ICIQ-MLUTSsex) Overall Symptom and Bother Scores.

Change From Baseline to End of Treatment in Overactive Bladder Questionnairre (OAB-q) Symptom Bother Score

Number of Participants With Change From Baseline in the Global Assessment Score of the Patient Perception of Bladder Condition (PPBC)

Patient Perception of Treatment Benefit at the End of Treatment in the Global Assessment Score of the Benefit, Satisfaction, and Willingness (BSW) Questionnaire

Change From Baseline in International Consultation on Incontinence Modular Questionnaire Female Sexual Matters Associated With Lower Urinary Tract Symptoms (ICIQ-FLUTSsex)Overall Symptom and Bother Scores.

Change From Baseline in the MCUI Behavior Therapy Stratified

Change From Baseline in the Medical Care Use Index (MCUI) Medical Resource Utilization in the Past 3 Months

Change From Baseline in the Treatment Satisfaction Visual Analog Scale (TS-VAS)

Change From Baseline to Each Visit in OAB-q Health Related Quality of Life (HRQL) Total Score

Change From Baseline in Work Productivity Assessment Index (WPAI)

Change From Baseline to End of Treatment in Mean Parameters Per 24 Hours Recorded in 3-day Diary

Compliance

Side Effects

Time to Continence

Change From Baseline in the Number of Incontinence Episodes Per 24 Hours Measured by Voiding Diaries.

Mean Proportion of Bowel Movements With Satisfaction Per Day

Average Score of Ease of Passage During Defecation Per Day

Colonic Filling at 6 Hours

Colonic Transit at 24 Hours

Colonic Transit at 48 Hours

Mean Number of Stools Per Day

Mean Score of Stool Consistency Per Day

Proximal Colonic Emptying Time

Time to Gastric Emptying

Change in Maximal Cystometric Capacity (mL)

Number of Urinary Incontinence Episodes Per 24 Hour Period

Number of Micturations Per 24 Hour Period

Number of Nocturia Episodes Per 24 Hour Period

Parkinson's Disease Quality of Life Scale (PDQOL)

Intervention	Participants (Number)
	Improvement from Baseline to End of Treatment	No Improvement from Baseline to End of Treatment
Placebo	231	131
Solifenacin Succinate	278	90

Intervention	Participants (Number)
	Benefit from Treatment - No	Benefit from Treatment - Little	Benefit from Treatment - Much	Benifit from Treatment - N/A	Satisfied with Treatment - No	Satisfied with Treatment - Yes	Willingness to Continue - No	Willingness to Continue - Yes
Placebo	115	90	109	2	129	187	128	188
Solifenacin Succinate	53	80	196	6	66	269	71	264

Intervention	ICIQ-FLUTSsex (Mean)
	Symptom- Baseline (N=302; 300)	Symptom- EOT (N=297; 291)	Symptom- Change at EOT (N=288; 288)	Bother- Baseline (N=281; 282)	Bother- EOT (N=263; 262)	Bother- Change at EOT (N=245; 249)
Placebo	4.9	3.9	-0.9	9.0	6.1	-3.1
Solifenacin Succinate	5.2	3.8	-1.3	10.0	6.6	-3.6

Intervention	Number of Days (Mean)
	days with timed voiding- Baseline (N=364; 365)	days with timed voiding- EOT (N=356; 360)	days with timed voiding-Change at EOT(N=347; 350)	days with fluid management-Baseline(N=368; 369)	days with fluid management- EOT (N=355; 366)	days with fluid management-Change at EOT(349; 360)	days w/ pelvic floor exercises-Baseline(364; 366)	days w/ pelvic floor exercises- EOT (N=352; 358)	days w/pelvic flr exercises-Change atEOT(344; 349)	days with biofeedback- Baseline (N=359; 360)	days with biofeedback- EOT (N=352; 358)	days with biofeedback- Change at EOT (N=338; 343)	days w/ electrical stimulation-Baseline (358; 362)	days w/ electrical stimulation- EOT (N=352; 358)	days w/ elec stimulation-Change at EOT(N=337; 345)
Placebo	14.8	10.3	-4.0	21.3	15.1	-6.3	8.5	12.1	3.4	0.4	0.0	-0.4	0.0	0.0	0.0
Solifenacin Succinate	12.1	7.4	-5.3	22.1	11.5	-11.0	9.2	5.5	-3.2	0.1	0.0	0.0	0.1	0.1	0.0

Intervention	Number of categorical items (Mean)
	physician office visits- Baseline (N=371; 375)	physician office visits- EOT (N=362; 366)	physician office visits- Change at EOT(359; 365)	urinary tract infections-Baseline (N=371; 370)	urinary tract infections- EOT (N=358; 362)	urinary tract infections-Change at EOT (355; 356)	skin rashes- Baseline (N=367; 368)	skin rashes- EOT (N=354; 357)	skin rashes- Change at EOT (N=347; 351)	falls- Baseline (N=365; 364)	falls- EOT (N=356; 358)	falls- Change at EOT (N=347; 349)	pad/diapers used/ week- Baseline (N=371; 375)	pad/diapers used/ week- EOT (N=360; 364)	pad/diapers used/ week- Change at EOT(N=357; 362)
Placebo	0.5	0.2	-0.4	0.1	0.1	-0.1	1.5	1.0	0.0	0.2	0.1	-0.1	10.0	9.8	-0.2
Solifenacin Succinate	0.5	0.2	-0.3	0.1	0.1	0.0	0.3	0.2	-0.1	0.2	0.5	0.2	10.4	8.3	-2.1

Intervention	TS-VAS (Mean)
	Baseline (N=363; 367)	End of Treatment (N=363; 367)	Change at EOT (N=352; 357)
Placebo	32.7	51.2	18.4
Solifenacin Succinate	29.0	67.4	38.2

Intervention	OAB-q HRQL Total Score (Mean)
	Baseline (N= 374 ; 377)	Week 4 (N=371; 370)	Change at Week 4(N=371; 370)	Week 8 (N=342; 356)	Change at Week 8 (N=342; 356)	Week 12 (N=318; 339)	Change at Week 12(N=318; 339)
Placebo	57.8	71.4	13.5	75.2	17.3	76.7	18.0
Solifenacin Succinate	56.4	76.0	19.3	80.5	24.4	82.2	25.8

Intervention	Percentage of indicated parameter (Mean)
	% work time missed- Baseline (N=175;175)	% work time missed- EOT (N=161;157)	% work time missed- Change at EOT (N=145;142)	% impairment while working- Baseline(N=203;194)	% impairment while working- EOT (N=193;197)	% impairment working-Change at EOT(N=172;175)	% overall work impairment- Baseline (N=174;175)	% overall work impairment- EOT (N=161;157)	%overall work impairment-Change at EOT(N=145;142)	%activity impairment- Baseline (N=368;375)	% activity impairment- EOT (N=357;362)	% activity impairment- Change at EOT(N=351;360)
Placebo	1.4	0.8	0.1	27.5	18.4	-8.7	28.5	20.8	-8.2	38.6	23.4	-14.7
Solifenacin Succinate	1.1	0.5	-0.5	27.6	13.2	-14.6	28.2	14.1	-12.9	37.3	19.2	-18.1

Intervention	Number of Category Events / 24 Hours (Mean)
	Micturitions- Baseline (N=363;369)	Micturitions- End of Treatment (N=363;369)	Micturitions- Change at EOT (N=363;369)	Incontinence Episodes- Baseline (N=267;268)	Incontinence Episodes-End of Treatment (N=267;268)	Incontinence Episodes-Change at EOT (N=267;268)	Urgency Episodes- Baseline (N=364;369)	Urgency Episodes- End of Treatment (N=364;369)	Urgency Episodes- Change at EOT (N=364;369)	Nocturia Episodes- Baseline (N=309;313)	Nocturia Episodes- End of Treatment (N=309;313)	Nocturia Episodes- Change at EOT (N=309;313)	Nocturnal Voids- Baseline (N=329;326)	Nocturnal Voids- End of Treatment (N=329;326)	Nocturnal Voids- Change at EOT (N=329;326)
Placebo	11.85	10.49	-1.36	2.80	1.56	-1.24	5.70	3.86	-1.84	1.57	1.09	-0.48	1.89	1.41	-0.48
Solifenacin Succinate	11.73	9.50	-2.23	2.92	1.07	-1.85	5.72	2.66	-3.05	1.74	1.11	-0.63	1.99	1.29	-0.70

Intervention	milliliters (mL) (Median)
Baseline Maximal Cystometric Capacity	95
One Month Maximal Cystometric Capacity	473.50